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Joseph F. Costello 
Loyola University Chicago 
THE ROLE OF METHYLATION AND CHROMATIN STRUCTURE IN THE 
REGULATION OF THE 06-METHYLGUANINE DNA 
METHYLTRANSFERASE GENE IN HUMAN GLIOMA CELLS 
There is considerable interest in identifying factors responsible for expression 
of the 0-6-methylguanine DNA methyltransferase (MGMT) gene as MGMT is a 
major determinant in the response of glioma cells to the chemotherapeutic agent 1,3 
bis(2-chloroethyl)-1-nitrosourea (BCNU). Since the majority of glioma cells express 
the MGMT gene, understanding factors that regulate MGMT expression is critical 
for the design of therapeutic strategies to inhibit MGMT expression and thereby 
overcome BCNU resistance. MGMT expression is presumed, but not proven to be 
regulated at the transcriptional level. Consistent with a transcriptional level of 
regulation, preliminary studies suggested that cytosine methylation may be one 
factor that influences MGMT expression. This dissertation was therefore designed 
to address the role of cytosine methylation in MGMT gene expression in human 
glioma cells. 
In order to develop the probes for examining methylation within the MGMT 
gene, a map of the coding sequences of the MGMT gene was generated by screening 
a genomic library (derived from a human fibroblast cell line) with an MGMT cDNA 
probe. Twenty MGMT genomic clones were isolated, mapped with restriction 
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enzymes (RE) and aligned, yielding a map of the gene containing four translated 
exons spread over > 80 kb. Several regions of the cloned MGMT gene with an 
overabundance of potential methylation sites (CpG dinucleotides) were identified 
with RE that recognize and cleave DNA at various CpG containing sequences. 
These and other regions across the body of the MGMT gene were then used to 
analyze MGMT gene methylation in human glioma cells. 
To determine if methylation in the body of the gene correlates with MGMT 
expression, the methylation status of CpGs throughout the body of the MGMT gene 
were examined in nine human glioma cell lines exhibiting a wide range of MGMT 
expression. Methylation in the body of the MGMT gene was analyzed by Southern 
blot analysis of glioma DNA digested with methylation sensitive REs. All of the 
MGMT gene regions tested were methylated in the MGMT expressing (MGMT+) 
glioma cells and relatively unmethylated in the nonexpressing cells (MGMT-). 
Quantitative analysis of methylation at an intron I CpG demonstrated graded 
methylation and a strong, positive correlation between methylation and glioma 
MGMT mRNA levels. These results suggest that methylation is uniform over the 
entire body of the MGMT gene and correlates in a direct, graded fashion with 
MGMT expression. This correlation is consistent with an indirect mechanism by 
which uniform methylation over the body of the MGMT gene may influence 
chromatin structure and hence MGMT expression. 
To determine if the association between methylation in the body of the 
MGMT gene and MGMT expression is mediated by changes in chromatin structure, 
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the accessibility of RE to the MGMT gene within intact nuclei was assessed. The 
unmethylated body of the MGMT gene was clearly more accessible to RE in nuclei 
from all MGMT- glioma cell lines tested relative to the methylated gene in nuclei 
from MGMT+ cells. The only accessible sites within the MGMT+ nuclei 
corresponded exactly to the few sites that were also unmethylated. These 
experiments demonstrate that methylation and chromatin structure in the body of 
the MGMT gene are closely linked, and are likely involved in MGMT expression. 
To determine if promoter methylation is also an important component of 
MGMT expression, this dissertation research addressed the complex interactions 
between methylation, chromatin structure, and in vivo transcription factor 
occupancy in the MGMT promoter of glioma cells. The level of MGMT promoter 
methylation, assessed by linker mediated PCR, was also graded across the cell lines 
(at 21 of 25 CpGs tested), but correlated in an inverse, rather than direct fashion 
with MGMT expression. The basal promoter in MGMT+ glioma cells was entirely 
accessible to RE, suggesting that this region may be free of nucleosomes. The basal 
promoter in MGMT- nuclei was entirely inaccessible to RE, supporting the idea that 
methylation and chromatin structure in the promoter are also associated. Despite 
the presence of the relevant transcription factors in all the cells examined, in vivo 
footprinting showed DNA-protein interactions at 6 Spl binding sites and one novel 
binding site in MGMT+ glioma cells but no such interactions in MGMT- cells. In 
contrast to previous in vitro studies, these data indicate that Spl is an important 
component of MGMT transcription. The data also strongly suggest that 
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methylation and chromatin structure, by determining whether Spl and other 
transcription factors can access the MGMT promoter, set the transcriptional state 
of the MGMT gene. 
In summary, these data provide compelling evidence for the involvement of 
methylation and chromatin structure, both in the promoter and body of the MGMT 
gene, in the regulation of MGMT expression. If these factors are also critical in 
glioma cells within tumors, the "accessible" chromatin in the MGMT expressing, and 
hence BCNU resistant, glioma cells may be a good target for inhibition of MGMT 
expression, possibly through triple helix formation. 
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CHAPTER I 
INTRODUCTION 
Gliomas are the most prevalent form of primary brain cancer and include 
tumors arising primarily from astrocytes, but also less frequently, from 
oligodendrocytes and ependymal cells. All patients with gliomas eventually die from 
their tumors, often within months or a few years of diagnosis, unless other diseases 
predominate (Ransohoff, et al., 1991). Although the etiology of gliomas is unknown, 
late age of onset, poor neurological status and significant residual tumor volume 
following surgery are factors intimately associated with decreased length of survival 
(Ransohoff, et al., 1991). As the incidence of gliomas is increasing in the United 
States (Greig ..fi_fil., 1990), there is considerable interest in elucidating the 
biochemical and genetic defects leading to glioma formation and malignant 
progression, and in developing effective therapies to treat gliomas. 
Gliomas are classified by neuropathologic criteria into stages of increasing 
malignancy, from benign to anaplastic to glioblastoma multiforme (Ransohoff, et 
al., 1991). These stages represent a continuum of glioma progression within each 
patient, although many patients do not survive through the anaplastic stage. 
Increased malignancy is closely associated with decreased survival time. Precise 
molecular and cytogenetic changes occurring at each stage of glioma progression 
have recently been described and may eventually be used in conjunction with the 
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neuropathologic criteria for more accurate diagnosis of the degree of malignancy 
(Collins and James, 1993). Such accuracy in diagnosis is critical, as the 
malignancy stage strongly determines the response to and usefulness of various 
therapies currently used to treat gliomas (Weingart and Brem, 1993). 
The initial treatment for gliomas is surgical removal of the tumor. However, 
because these tumors have very irregular shapes and ill-defined borders, residual 
tumor cells remain in the patient following surgery, and invariably, the tumor 
recurs (Ransohoff, et al., 1991). Surgery is therefore followed with radiation therapy 
and often chemotherapy in attempt to eliminate the residual tumor cells. 
Gliomas are treated most effectively with the chemotherapeutic agent l,3-
bis( chloroethyl)-1-nitrosourea (BCNU)(Walker, et al., 1980). BCNU is useful in 
treating brain tumors for two reasons. First, the lipid soluble nature of BCNU 
molecules allows them to cross the relatively impermeable barrier between the blood 
vessel interior and brain tissue (the blood-brain barrier) and reach the brain tumor 
site (Rall, et al., 1962). Second, the chloroethyl group adducts at the 0 6-position 
of guanine produced by BCNU rearrange to form DNA interstrand crosslinks that 
are cytotoxic to rapidly dividing cells (Kohn, 1977; Ewig and Kohn, 1978; Erickson, 
et al., 1978). Because the vast majority of normal brain cells are in a nondividing 
state, BCNU is much more toxic to the tumor cells. Initially, responses to BCNU 
(tumor stasis or partial tumor regression) are seen in approximately one-half of all 
glioma patients treated with BCNU (Walker, et al., 1980). At undefined points 
during or after recurrence however, the majority of these gliomas become resistant 
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to BCNU chemotherapy, and the tumor progresses rapidly (Weingart and Brem, 
1993). Research designed at elucidating the mechanisms conferring BCNU 
resistance in glioma cells is paramount for improving the currently ineffectual 
treatment of resistant gliomas. 
Seventy percent of human glioma cell lines and many human glial tumors 
are resistant to the cytotoxic effects of BCNU (Kornblith,..n..fil. 1981; Sariban, et al., 
1987; Day, et al. 1990; Ostrowski, et al., 1991). BCNU resistance is conferred by the 
DNA repair protein, 0 6-methylguanine DNA methyltransferase (MGMT) (Pegg,~ 
al., 1982; Tano, et al., 1990). MGMT removes the BCNU-induced chloroethyl group 
adducts from 0 6-guanine in the glioma cell DNA, preventing the formation of 
cytotoxic interstrand crosslinks (Erickson, et al., 1980). Thirty percent of BCNU-
sensitive brain tumor cell lines are devoid of the MGMT mRNA and MGMT protein 
despite the presence of an intact MGMT gene (Day, et al., 1990, Ostrowski, et al., 
1991; Costello, et al., 1994). This and other observations suggest that the BCNU-
sensitive phenotype of these brain tumor cells appears to result, at least in part, 
from suppression of MGMT gene transcription (Ostrowski, .Il_fil., 1991, Costello, et 
al., 1994a). Examining factors that may suppress MGMT gene transcription is 
essential for designing therapeutic strategies to overcome BCNU resistance in 
MGMT-expressing brain tumors. 
Transcriptional control of gene expression is mediated by a variety of 
mechanisms including DNA cytosine methylation (reviewed in Jost and Saluz, 1993). 
In the DNA of all human cells, a subset of cytosines in the dinucleotide CpG are 
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modified by an endogenous methylating enzyme (Bestor, et al., 1988). Addition of 
a methyl group to cytosines of a CpG is a normal DNA modification that plays a 
central role in transcriptional regulation of gene expression (Jost and Saluz, 1993). 
Regions of DNA known as CpG islands contain clusters of CpG dinucleotides 
(relative to the majority of bulk DNA which is CpG-depleted) that are normally 
maintained in the unmethylated state (Bird, 1986). Because the MGMT cDNA has 
an overabundance of CpGs (Tano, et al., 1990), one or more of the MGMT exons 
comprising the cDNA sequence may be part of a CpG island. Processes which are 
associated with abnormal de novo CpG island methylation such as tumorigenesis 
(De Bustros, et al., 1988), viral transformation (Vertino, et al., 1993) and cell 
culture (Antequera, et al., 1990), are also frequently associated with loss of MGMT 
gene expression (Green, et al., 1990; Fornace, et al., 1990). Abnormal methylation 
of potential MGMT gene-associated CpG islands could therefore be one mechanism 
by which transcription of the MGMT gene is suppressed. Indeed, preliminary 
evidence suggests that the methylation status of MGMT exons is altered in virtually 
all MGMT nonexpressing (MGMT-) cell lines tested (Pieper, et al., 1991; Wang, et 
al., 1992). The purpose of my dissertation research is thus to determine the 
relationship between cytosine methylation and MGMT expression in human brain 
tumor cells. I have proposed three specific aims to examine this relationship: 
Aim 1: To isolate regions of the MGMT gene that contain CpG island 
characteristics. 
Aim 2: To determine the relationship between the methylation status of potential 
MGMT gene-associated CpG islands and MGMT gene expression in human glioma 
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cells. 
Aim 3: To examine the mechanism by which methylation may influence MGMT 
expression in human glioma cells. 
The hypothesis that this dissertation research attempts to validate is that 
glioma cells regulate expression of the MGMT gene by virtue of differential 
methylation of MGMT gene-associated CpG islands. Methylation of the CpG island 
regions, through methylated DNA binding proteins, alters the local chromatin 
structure such that accessibility of other proteins necessary for transcription of the 
MGMT gene is altered. 
Understanding the relationship between cytosine methylation and MGMT gene 
expression is important because it may ultimately be useful in the development of 
therapies designed to inhibit MGMT expression. Inhibition of MGMT expression 
followed by BCNU administration might then enhance the antitumor activity of 
BCNU, significantly reduce the number of residual tumor cells following surgery 
and thereby improve chemotherapy of BCNU-resistant gliomas. 
Primm Brain Cancer 
CHAPTER II 
LITERATURE REVIEW 
Approximately 16,000 new cases of primary brain cancer occur each year and 
the incidence is increasing in the United States (RansohofT, et al., 1991). The 
etiology of primary brain cancer is unknown. Primary brain cancer rarely, if ever, 
metastasizes outside the central nervous system, yet many forms of primary brain 
cancers are fatal (Weingart and Brem, 1993). 
Gliomas are the most prevalent form of primary brain cancer. Gliomas 
include tumors arising predominantly from astrocytes, but also less frequently from 
oligodendrocytes or ependymal cells. All glioma patients die of their tumors within 
months or a few years of diagnosis. The most important prognostic criteria for 
increased length of survival for glioma patients are younger age of onset, better 
neurologic status, and decreased residual tumor volume following surgical resection 
of the tumor (RansohofT, et al., 1991). 
Gliomas are classified in grades of malignancy according to neuropathologic 
and genetic criteria. Gliomas often progress from benign to anaplastic to 
glioblastoma multiforme (GBM) within each patient, although many patients die 
before the most malignant stage (GBM) is reached. At diagnosis, all gliomas are 
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visible by magnetic resonance imaging (MRI). Neuropathologically, benign tumors 
are identified by the presence of microcysts and uniformly sized nuclei, while 
anaplastic gliomas are identified by hyperplasia of blood vessel endothelial cells 
within the tumor, and GBMs are identified by the presence of geographic necrosis 
(Kornblith, et al., 1985). Recently, identification of specific genetic abnormalities 
occurring at high frequencies within each of the neuropathologically-defined 
malignancy stages have yielded genetic definitions of glioma progression. The 
genetic changes identified in gliomas involve deletions, gene amplifications, and 
mutations, with many of the changes imparting a growth advantage in the tumor 
cell. Regions of chromosomal deletion are thought to involve the loss of tumor 
suppressor genes, whereas gene amplifications in gliomas are exclusively associated 
with oncogenes. Mutations within chromosomes may involve either tumor 
suppressor genes or oncogenes. Genetic changes found at similar frequencies in all 
stages, such as deletions within chromosome 13q, 17p and 22q (James, et al., 1988; 
Fults, et al., 1990), may be related to tumorigenesis and likely occur early in tumor 
progression. Progression from benign to malignant glioma is accompanied by 
additional deletions, within chromosome 9p (Miyakoshi, et al., 1990) and 19q (von-
Deimling, et al., 1992), mutations in the tumor suppressor gene p53 (James, et al., 
1989), and/or MDM2 gene amplification (Collins and James, 1993). Genetic 
changes found only in later stages (GBM), such as complete loss of one copy of 
chromosome 10, deletions with lOp and lOq (Karlbom, et al., 1993), and 
amplification of the epidermal growth factor receptor (in 40% of all 
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GBMs)(Libermann, et al., 1985), may be exclusively involved in malignant 
progression. The frequent loss of one copy of chromosome 10 in GBMs is especially 
relevant to this dissertation, as the MGMT gene resides on this chromosome 
(Rydberg, et al., 1990; Natarajan, et al., 1992). Genetic analysis of gliomas in 
conjunction with neuropathology may thus provide for more accurate diagnosis of 
malignancy stage. Such accuracy in diagnosis is critical, as the malignancy stage 
strongly determines the response to, and usefulness of, various therapies currently 
used to treat gliomas. 
The standard therapy for gliomas involves surgical removal of the tumor, 
followed by radiation therapy, and often chemotherapy. While there are no curative 
therapies available, surgical excision of gliomas is the treatment most clearly 
associated with increased survival. However, gliomas are nonencapsulated tumors 
and grow in a highly irregular, multidirectional fashion making complete surgical 
resection impossible. Radiation and chemotherapy are therefore used to eliminate 
residual tumor cells following surgery. Radiation treatment of gliomas also has 
survival benefit, but recurrent gliomas and especially GBMs eventually become 
unresponsive to further radiation therapy (Weingart and Brem, 1993). A variety of 
chemotherapeutic agents have been tested for efficacy against gliomas, with initial 
responses (tumor stasis or partial tumor regression) to several agents observed in 
approximately 50% of glioma patients (Wilson, et al, 1970; McVie, 1993). As with 
radiation therapy, gliomas also become unresponsive or resistant to chemotherapy. 
Understanding and eventually inhibiting the mechanisms by which glioma cells 
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become resistant to chemotherapy is a current goal of cancer research. 
Understanding these resistance mechanisms relies first on a clear knowledge of the 
mechanisms by which the chemotherapeutic agents exert their cytotoxicity and 
antitumor activity. 
Chloroethylnitrosoureas (CENU) are a class of chemotherapeutic agents, of 
which 1,3 bis(2-chloroethyl)-l-nitrosourea (BCNU) is the most commonly used and 
most effective antitumor agent against gliomas (Wilson, ..e!.J!l, 1970; Walker, ..rt...al., 
1980). BCNU is a lipid soluble DNA alkylating agent, and when administered 
intravenously to glioma patients, can easily cross the blood-brain barrier to reach 
the tumor site (Rall and Zubrod, 1962). BCNU spontaneously decomposes under 
physiological conditions to form a chloroethylating moiety and a carbamoylating 
moiety (Tong, et al., 1982). The chloroethylating moiety forms several DNA adducts 
including frequent N7-hydroxylethyl and N7-chloroethyl adducts on guanines and 
much less frequent 0 6-chloroethyl adducts on guanines (Tong, et al., 1982). A wealth 
of data indicates that the 0 6-chloroethyl group adducts on guanine are the adducts 
most relevant to the cytotoxicity induced by BCNU (reviewed in Erickson, 1991). 
Over a period of several hours, the 0 6-chloroethyl adducts undergo an 
intramolecular rearrangement to form a cyclized intermediate, 0 6-N1-ethanoguanine, 
and finally, through interaction with the cytosine on the complementary DNA 
strand, form a guanine-N1-cytosine-N3 DNA interstrand crosslink (Tong, et al., 
1982). The frequency of DNA interstrand crosslinks correlates well with degree of 
BCNU-induced cytotoxicity, supporting the idea that the crosslink is a relevant 
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cytotoxic lesion (Erickson, et al., 1980). Few if any BCNU-induced DNA interstrand 
crosslinks are formed in BCNU-resistant human glioma cell lines and xenografts. 
Accordingly, a great deal of research has been directed towards elucidating the 
mechanism by which resistant cells prevent BCNU-induced crosslink formation. 
0 6-Methylzmanine DNA Methyltransferase (MGMT) 
Initial investigations of mechanisms of CENU toxicity and CENU-resistance 
were significantly advanced by several studies in the late 1970s and early 1980s. 
After it was established that the alkylating moiety ofCENUs was capable of forming 
DNA interstrand crosslinks (Kohn, 1977; Ewig and Kohn, 1978), high levels of 
CENU-induced crosslinks were observed in CENU-sensitive human colon carcinoma 
cells (BE) but few or no crosslinks were detected in a CENU-resistant colon tumor 
cell line (HT29) (Erickson et al., 1978). The relationship between response to 
CENU and presence of DNA interstrand crosslinks was demonstrated in a dose-
dependent fashion with at least four different CENU (including BCNU) (Erickson, 
et al., 1980, 1980a). It was proposed that the lack of crosslinks in CENU-resistant 
cells was due to a DNA repair mechanism operating in these cells but absent from 
CENU-sensitive tumor cells (Ewig and Kohn, et al., 1978; Erickson et al., 1980a). 
In 1980, the CENU studies converged with other studies examining repair of 
DNA damage produced by the DNA methylating carcinogen N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG)(Day, ~., 1980). Human tumor cell lines tested for 
their ability to repair, and hence reactivate, MNNG-damaged adenovirus fell into 
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two groups. One group of tumor cell lines reactivated the MNNG-damaged 
adenovirus and was designated methylation repair positive, or Mer+. The group 
that was incapable of adenovirus reactivation, and hence incapable of methylation 
repair was termed methylation repair negative, or Mer-. Soon after this report, it 
was demonstrated in blinded studies that the CENU-resistant cell lines, which were 
capable of preventing CENU-induced crosslinks, were also Mer+ and the CENU-
sensitive cell lines were Mer- (Erickson, et al., 1980). Additional studies firmly 
defined the Mer phenotype on the basis of a cell's ability to reactivate MNNG-
treated adenovirus, prevent CENU-induced DNA interstrand crosslinks, and repair 
0 6-methylguanine in DNA (Day, et al. 1980a, and Erickson, et al., 1980a). A DNA 
repair protein responsible for the CENU resistance, termed 0 6-methylguanine DNA 
methyltransferase, was subsequently identified in mouse liver (Bogden, et al., 1981), 
rat liver (Pegg, et al.,1983), and normal human liver (Pegg, et al., 1982). 
0 6-methylguanine DNA methyltransferase (MGMT) is a major determinant 
in the sensitivity of glioma cells to CENU. MGMT confers resistance to CENU 
(and other agents that alkylate the 0 6-position of guanine) by transferring alkyl 
group adducts, including chloroethyl adducts, from the 0 6-position of guanine in 
DNA to a cysteine acceptor site at cys-145 within the MGMT protein (reviewed in 
Pegg, 1990). MGMT can also form covalent interactions with the CENU-DNA 
cyclized intermediate (Gonzaga, et al., 1992). The transfer reaction restores guanine 
to its unmodified state, thus preventing crosslink formation, and inactivates one 
MGMT molecule per lesion. MGMT does not require any other proteins or 
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cofactors for the transferase activity in vitro. Although CENU resistance may 
involve mechanisms other than MGMT in a limited number of cases (Karran and 
Stephenson, 1990; Bronstein, et al., 1992; Branch, et al., 1993), the demonstration 
that specific pharmacologic inhibition of MGMT sensitizes CENU-resistant cells 
(Zlotogorski and Erickson, 1983 and 1984; Dolan, .rt_fil., 1990) clearly establishes 
a dominant role for MGMT in conferring CENU resistance. This and other studies 
(Futscher, et al., 1989; Marathi, et al., 1993) also demonstrate the feasibility and 
usefulness of inhibiting MGMT for therapeutic benefit. 
The cDNA for the 0 6-methylguanine-DNA methyltransferase has been cloned 
(Tano, et al., 1990; Hayakawa, et al., 1990; Rydberg, et al., 1990), the chromosomal 
location of the MGMT gene defined (Rydberg, et al., 1990; Natarajan, .!1.Jtl., 1992) 
and the presence of MGMT mRNA verified in Mer+ cells (Rydberg, et al., 1990). 
The human MGMT cDNA was first isolated by transforming repair deficient 
bacteria with a cDNA library made from a Mer+ cell line, followed by phenotypic 
rescue of repair proficient cells in MNNG-containing media (Tano, et al., 1990). 
The protein coding portion of the MGMT cDNA is 624 nt and is flanked on the 5' 
end by at least 96 nt and 224 nt on the 3' end. The cDNA sequence also contains 
a consensus sequence for poly-A tail addition. The predicted amino acid sequence 
does not contain any clear nuclear localization signals as would be expected for a 
DNA repair protein. The MGMT protein is, however, localized exclusively in the 
nucleus (Ayi et al., 1992). 
The level of MGMT expression in normal human tissue is cell type specific, 
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tissue specific and varies among individuals. Normal human brain and lung are 
low in MGMT activity and mRNA relative to liver, which has the highest level of 
MGMT in any normal tissue tested (Pegg, 1978; Citron, et al., 1991). Different cell 
types within the liver (Swenberg, et al., 1982) and kidney (Wani, et al., 1992) have 
10-fold variations in MGMT levels. For example, MGMT mRNA is highest in distal 
tubular and glomerular epithelial cells and low in the Bowman's capsule cells, 
collecting and proximal tubular cells. The MGMT expression levels in specific cells 
of the liver and kidney correlate well with variations in persistence of 0 6-
alkylguanine lesions in these cells following exposure to alkylating agents. It has 
not been determined whether the levels of MGMT vary in a cell type specific 
manner in normal human brain (eg. neurons versus glia). MGMT measurements 
in peripheral blood lymphocytes showed a 7-fold interindividual variance 
(D' Ambrosio, et al., 1990), although no such interindividual variation was seen in 
MGMT mRNA levels in human kidney cells (Wani, et al., 1992). 
The level of MGMT expression in human glioma tissue is highly variable. A 
one hundred-fold variation in MGMT activity among 27 unrelated glioma samples, 
including 22% with no detectable MGMT activity, was reported in one study 
(Citron, et al., 1991). Another study of 60 glioma samples showed a similar 
frequency (27%) of MGMT deficient gliomas (Silber,..tl.fil., 1993). These studies are 
consistent with the reported 20-30% of MGMT deficient human glioma cell lines 
(Ostrowski, et al., 1991). The frequency of MGMT deficient gliomas is not a 
universal finding however (Wiestler, et al., 1984) and even the existence of such 
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tumors is debated by some researchers. 
MGMT expression is presumed, but not proven, to be regulated at the 
transcriptional level. Although all the glioma cell lines tested have an intact 
MGMT gene, the glioma cell lines devoid of MGMT activity are also lacking the 
MGMT protein, as measured by western blot analysis, and MGMT mRNA, as 
measured by northern blot analysis (Ostrowski, ..H__fil., 1991). Using the more 
sensitive PCR technique however, small amounts of MGMT mRNA are detectable 
in populations of some Mer- cell lines, indicating that MGMT transcription may 
occur at very low levels, or at higher levels with a concomitant decrease in mRNA 
stability, in these cell lines (Pieper, et al., 1990). A defect at the transcriptional 
level appears more likely though, as there were no differences in MGMT mRNA 
stability in cell lines with vastly different levels of MGMT mRNA (Kroes and 
Erickson, 1992). Attempts to measure transcription rates by detection of MGMT 
heteronuclear RNA (hnRNA), either through nuclear run-on assays or PCR, have 
been unsuccessful, even in cells with high levels of MGMT mRNA (Kroes and 
Erickson, 1992; Russell Pieper, personal communication). This may indicate that 
in MGMT expressing cells, the rate of MGMT transcription is too slow to detect 
and/or that other events such as processing of MGMT hnRNA occur rapidly after, 
or even concurrent with, transcription. Consistent with transcriptional differences 
in MGMT expression, a recent study has demonstrated that the level of cytosine 
methylation in MGMT exons is consistently decreased in MGMT deficient tumor 
cells (Pieper et al., 1991). 
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cytosine Methylation and Gene Egression 
Methylation of the CS-position of cytosine is a normal, covalent DNA 
modification found in all mammalian cells. Methylation occurs exclusively at the 
dinucleotide CpG and approximately 60% of all CpGs are methylated (Bestor, et al., 
1984). Cytosine methylation is accomplished by enzymatic transfer of a methyl 
group from S-adenosylmethionine to a cytosine within a CpG. The preferred 
substrate for the enzyme, cytosine methyltransferase (MTase), is hemimethylated 
DNA (Gruenbaum, et al., 1982). The methylation reaction occurs during DNA 
replication (Leonhardt, et al., 1992), allowing methylation patterns to be transmitted 
in a stable manner through each cell generation, and is thus termed maintenance 
methylation. In mammalian development, establishment of methylation patterns 
occurs in the postimplantation embryo by de novo methylation. Although the 
mechanism responsible for de novo methylation is unknown, establishment of 
appropriate methylation levels is critical for normal development and survival in 
mammals (Li, et al., 1993). 
The distribution of the potential methylation site, CpG, is nonrandom. The 
overall genome is depleted ofCpGs 5-fold from the expected CpG frequency, derived 
from base composition alone (McClelland and lvarie, 1982). The genome-wide CpG 
depletion is thought to result, at least in part, from the spontaneous deamination 
of methylated cytosines to thymine (Salser, 1977). This mechanism of CpG 
depletion is consistent with the observed overabundance of TpG and ApG 
dinucleotides in the genome. Accordingly, methylation and subsequent deamination 
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tend to deplete potential methylation sites, and conversely, CpGs are more likely to 
be preserved through many cell divisions by being maintained in the unmethylated 
state. 
In contrast to the majority of the genome, short segments of DNA, together 
comprising approximately 1 % of the genome, have the theoretically expected 
frequency of CpGs and are termed CpG islands. CpG islands are defined as 
regions of DNA characterized by the following three features: 1) 0.3 to 3.0 kb in 
length, 2) the expected frequency of CpG dinucleotides (compared to the 5-fold 
CpG depletion seen in the genome overall), and 3) a guanine + cytosine (GC) 
content of >50% (compared to <40% in the genome overall) (Gardiner-Garden and 
Frommer, 1987). Additionally, CpG islands are normally maintained in the 
nonmethylated state, thus increasing the likelihood that these CpGs will be 
preserved (Bird, 1986). Approximately 45,000 CpG islands are present in the 
human genome and, similar to CpGs, are distributed non-randomly throughout the 
genome (Antequera and Bird, 1993). The non-random distribution and maintenance 
of CpG islands in the unmethylated state implies that there is some functional 
importance associated with CpG islands. 
Virtually all known CpG islands are associated with genes, predominantly in 
the 5' region of genes, but also less frequently in 3' gene regions (Gardiner-Garden 
and Frommer, 1987). The promoters for all known housekeeping genes (genes 
essential for cell survival) are within, or part of, a CpG island. Forty-five thousand 
of the estimated 80,000 genes in the human genome are likely associated· with a 
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CpG island (Antequera and Bird, 1993). Because the MGMT gene is considered a 
housekeeping gene it is likely that the MGMT promoter is associated with a CpG 
island. Because the MGMT cDNA is very GC rich and has an overabundance of 
CpGs, it is possible that one or more of the MGMT exons may also be part of a 
CpG island. 
A variety of evidence indicates that CpG islands have a critical role in the 
regulation of genes with which they are associated. CpG islands invariably contain 
nucleosome free regions that are very accessible to diffusible factors (Tazi and Bird, 
1990). Such accessible DNA sequences are essential for interaction with 
transcription factors and maintaining a transcriptionally active state. Although the 
nucleotide sequence among individual CpG islands is highly variable, most CpG 
islands have consensus sites for a common set of transcription factors (eg. Spl), 
and these sites are indeed essential for transcription of the associated gene (Pugh 
and Tjian, 1990). Although CpG islands are usually unmethylated, the de novo 
methylation of CpG islands does occur, concomitant with suppression of 
transcription from the associated gene. The methylation status of CpG islands is 
therefore a critical parameter of gene regulation. 
Changes in the methylation status of CpGs within CpG islands and CpGs 
located in non-island sequences may occur as a result of one or several normal (X 
chromosome inactivation, imprinting, tissue specific gene expression) or abnormal 
(tumorigenesis, viral transformation, cell culture) processes (reviewed in Jost and 
Saluz, 1993). The aberrant methylation changes noted in many, but not all, tumor 
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cells are described as widespread hypomethylation (Goelz and Vogelstein, 1985) and 
regional hypermethylation (De Bustros, .n...fil,, 1988). Widespread hypomethylation 
refers to an overall decrease in the level of methylated CpGs in the genome and 
probably involves gene and non-gene sequences. Regional hypermethylation in 
tumor cells occurs at normally unmethylated CpG islands. The frequency of 
methylation changes in tumor cells is not clear, although one study of the calcitonin 
gene-associated CpG island demonstrated hypermethylation in only 2 of 31 chronic 
myelogenous leukemia (CML) patients in less advanced stages (Nelkin, et al., 1991). 
Hypermethylation was detected much more frequently (11 of 12 patients) in 
advanced stage CML. This study suggests that methylation changes may contribute 
to tumor cell progression. In contrast to CML, colon cancer patients have frequent 
abnormal CpG island methylation in the calcitonin gene and chromosome 17p (a 
region thought to harbor a tumor suppressor gene) in the early, benign stages 
(Silverman, et al., 1989), suggesting that methylation changes may also contribute 
to tumorigenesis. Gliomas have not been tested for similar changes in methylation. 
Tumorigenic transformation produced by viral infection or by transfection of 
oncogenes also alters methylation within affected cells (Vertino, ~., 1993). 
Methylation changes in cultured cell lines have also been noted, with an estimated 
one-half of all CpG islands being subject to aberrant hypermethylation (Antequera, 
et al., 1990). The mechanisms involved in, or leading to, abnormal changes in 
methylation are not defined, although increased expression of the MTase gene has 
been noted in some tumor cells (El-Deiry, et al., 1991). As the MTase is a 
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maintenance methylase, overexpression of MTase alone cannot account for the high 
level of de novo methylation in tumor cells or cell lines. In X chromosome 
inactivation, tumorigenesis, viral transformation, and cell culture, the documented 
methylation changes are also accompanied by changes in expression of the 
associated gene. Since the tumorigenic state, cell culture, and viral transformation 
are conditions also associated with frequent loss of MGMT gene expression, it 
seems likely that the methylation status of the MGMT gene, possibly including 
MGMT gene-associated CpG islands, is altered in at least some of the cells in these 
conditions. 
In the majority of genes studied, the methylation status of CpGs in the 
promoter correlates in an inverse, all-or-none fashion with gene expression. 
Whether the methylation status of a given promoter is a result of normal or 
abnormal processes, methylated promoters are associated with inactive genes and 
unmethylated promoters are associated with active genes (reviewed in Saluz and 
Yost, 1993). During X-chromosome inactivation for example, the CpG island 
promoter for the phosphoglycerate kinase (PGK-1) gene becomes methylated at 119 
of 121 CpGs on the transcriptionally inactive X chromosome but remains 
unmethylated at all 121 sites on the active X chromosome (Pfeifer,~., 1990). 
The inactivation of the X-linked genes precedes the CpG island methylation 
however, indicating that for these genes, methylation may serve to "lock in" the 
transcriptionally inactive state rather than cause gene silencing. On the other hand, 
methylated, inactive genes (including PGK-1) can be reactivated by exposing cells 
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to the demethylating agent 5-azacytidine. Additionally, a large number of studies 
have demonstrated that in vitro methylated genes are transcriptionally inactive 
when transfected into cells, whereas the unmethylated, transfected genes are 
expressed (Stoger, et al., 1993; Boyes and Bird, 1992). In general, unmethylated 
promoters are necessary but not sufficient for gene expression. 
As opposed to promoter methylation, the relationship between the methylation 
status of CpGs in the body of genes and gene expression is poorly defined. A direct, 
rather than inverse, correlation between body methylation and gene expression has 
been noted in several studies. For several X chromosome linked (Wolf, .§.J!l., 1984) 
and autosomal (Razin and Riggs, 1980; Stein, et al., 1983) genes, extensive 
methylation of over entire body sequences is associated with active transcription. 
In the transcriptionally inactive state, the body of these genes is variably 
methylated, but generally much less methylated than the body of active genes. The 
body of the gene encoding the developmentally regulated transplantation antigen H-
2K is unmethylated in cells that do not express H-2K, but upon differentiation, the 
H-2K gene becomes methylated coincident with transcriptional activation (Tanaka, 
et al., 1983). The active H-2K gene can then be suppressed by 5-azacytidine-induced 
demethylation of the body of the gene, further strengthening the direct relationship 
between body methylation and gene expression. In other genes such as the 
maternally imprinted Igt2-r gene, methylation of the body of the gene correlates 
directly with expression, but only in a very specific region (2 kb of 130 kb 
analyzed)(Stoger, et al., 1993). In vitro methylation of CpGs in the body of genes, 
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without promoter methylation, influences gene activity (Keshet, et al., 1985). In yet 
other genes, no obvious relationship is detected between methylation and gene 
expression (McKeon, .n._m., 1982). Although a mechanism by which methylation 
in the body of genes influences gene expression has not been defined, the conserved 
methylation status of CpGs in the body and promoter of many genes suggests that 
there is functional importance associated with methylation of both of these regions. 
Additionally, the direct association between methylation and gene expression in the 
body of genes and inverse association in promoters suggests that body methylation 
and promoter methylation, by different mechanisms, may be involved in setting the 
expression state of genes as active or inactive. 
Two models have been proposed to mediate the relationship between 
methylation and gene expression (Antequera, et al., 1989). The first, "direct model" 
postulates that cytosine methylation interferes directly with the binding of 
transcription factors to their specific recognition sequence in regulatory regions of 
DNA. This model is supported by experiments comparing the transcriptional 
activity of methylated to nonmethylated cyclic adenosine monophosphate (cAMP) 
response element (CRE) sequence in cloned DNA. Methylation of a single cytosine 
within the CRE was sufficient to abolish both binding of the CRE binding protein 
to CRE and transcriptional activation of genes linked to CREs (Sanae and 
Schaffner, 1989). This mechanism however, is obviously limited to CpG-containing 
binding sites and is irrelevant to transcription factors such as Spl, whose binding 
is methylation independent (Harrington, et al., 1988). A second, "indirect model" 
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suggests that cytosine methylation interferes with transcription via proteins that 
bind specifically to methylated DNA (MeCPs) and alter the local DNA conformation 
such that these DNA regions become transcriptionally inactive (Antequera, .n._ru., 
1989, 1990). This model is supported by the identification of four such proteins 
that bind selectively to DNA containing methylated cytosines (Wang, et al., 1986; 
Antequera, et al., 1989; Jost and Hofsteenge, 1992; Lewis, et al., 1992). Additional 
evidence for the indirect model comes from experiments using methylation sensitive 
DNA restriction enzymes (17). The DNA recognition sequence of the restriction 
enzyme Mspl (CCGG) contains a potential methylation site (CpG dinucleotide). 
While Mspl cleaves naked DNA (no protein) irrespective of methylation, it does not 
cleave DNA at methylated CCGG sequences contained within isolated, intact nuclei 
(protein bound DNA), suggesting that MeCPs, if present, block Mspl accessibility 
to the DNA. The interrelationship of MeCPs with other chromosomal proteins (eg. 
histones) in the formation or maintenance of the methylation-related inactive 
chromatin is not understood. Methylation-related chromatin structures could 
explain why many genes, including MGMT, are not expressed in cells that contain 
all the relevant transcription factors (Antequera, et al., 1989). 
While methylation clearly can be involved in setting the state of gene 
activation/inactivation, a limited amount of studies suggest that graded 
methylation, both in promoter and body regions of genes may be associated with 
more graded levels of gene expression. One study used an artificial system in which 
the entire human a-globin gene was methylated to low, intermediate and high levels 
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in vitro and then transfected into HeLa cells (Boyes and Bird, 1992). In this study, 
both the level of methylation and binding of MeCPs correlated inversely with 
expression of the transfected Q-globin gene. Similar results were seen with SV40 
promoter containing constructs methylated in vitro and transfected into mouse cells 
(Levine, et al., 1992). These studies raise the possibility that methylation, in 
addition to being a mechanism associated with regulation of gene expression in an 
all or none fashion, may also be associated with subtle changes in the level of gene 
expression. 
Cell Culture 
CHAPTER III 
METHODS 
The ten glioma cell lines used were established from grade III-IV human 
astrocytomas and glioblastomas. The glioma cell lines used were A1235, CLA, CRO, 
NAT (L. Erickson, Loyola University Medical Center, Maywood, IL.) SF763, SF767 
(Brain Tumor Research Center, University of California, San Francisco, CA), 
Hs683, T98, U138, and U373 (purchased from American Type Culture Collection). 
The cell lines were all grown in a-minimal essential medium (Hyclone Laboratories) 
with 10% bovine calf serum (Hyclone), glutamine, vitamin B12/Biotin, sodium 
pyruvate, gentamycin and nonessential amino acids. The cell lines were maintained 
in log phase growth at 37°C in a 95% air;5% C02 atmosphere. 
MGMT cDNA probe SJ'llthesis - An MGMT cDNA was obtained by polymerase 
chain reaction (PCR) amplification of reverse transcribed T98 RNA using two 
MGMT-specific oligonucleotides. First strand synthesis was performed in a 20 µl 
reaction containing 1 µg of T98 mRNA, 1 X PCR buffer (10 mM Tris-Cl, pH 8.3/50 
mM KCl/3.0 mM MgC12/0.01% gelatin), 1 mM each of dCTP, dATP, dGTP and 
dTTP (Perkin Elmer Cetus (PEC) ), 0.32 µg oligo dT (Bethesda Research 
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Laboratories (BRL)) and 200 U Moloney murine leukemia virus reverse 
transcriptase (BRL). The reaction was incubated at 25°C for 10 min, 37°C for 1 hr, 
and 95°C for 10 min, followed by cooling on ice. 10 X PCR buffer (without 
magnesium), dNTP mix and ddH20 were added to give a final volume of 100 µl, 200 
µM each dNTP, and a 1 X PCR buffer concentration. Fifty pmol each of two 
primers complementary to the published MGMT cDNA (Tano, li...fil., 1990) were 
added to the reaction. The 5' primer was 5'-
AAGGTACCGTTTGCGACTTGGTACTTG-3' and the 3' primer was 5'-
TAGTCGACCATCCGATGCAGTGTTACACG-3'. Both primers contain 7 
nonMGMT-complementary nt at the 5' end (for cloning purposes). Three units of 
Taq polymerase (Perkin, Elmer, Cetus) were added and the reaction was amplified 
by PCR (95°C for 5 min followed by 30 cycles of 95°C for 30 sec, 55°C for 30 sec, 
and 72°C for 45 sec and a final incubation at 72°C for 10 min). The products of 
the reaction were electrophoresed through a 1.5% agarose gel and a gel slice 
containing the single PCR product (730 bp) was removed. The DNA was isolated 
from the gel slice by centrifugation (5 min, 12000 RPM) through glass wool (Alltech, 
Deerfield, II.), and was ethanol precipitated, and resuspended to 10 ng/µl in ddH20. 
Twenty-five ng of the purified amplification product was used to synthesize a 
radiolabelled MGMT cDNA probe by the random primer method (Feinberg, et al., 
1984) with [a-32P] dCTP (specific activity 3000 Ci/mmol, Amersham, Arlington 
Heights, IL.). The specific activity of the labelled MGMT cDNA was typically > 109 
cpm/µg. Human histone H3.3 cDNA was generated in the same manner as the 
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MGMT cDNA except with the following histone-specific primers: 5' primer, 5'· 
CCACTGAACTTCTGATTCGC-3'and3'primer,5'-GCGTGCTAGCTGGATGTCTT-
3'. 
Genomic Library Screenin& and Restriction Emme Mappin& 
A genomic library constructed from the DNA of a human fibroblast cell line 
(Wl38) inserted in the phage vector Lambda FIX II (Stratagene, La Jolla, CA.) was 
screened according to the manufacturer's protocol. Approximately 1 X 106 plaque 
forming units (PFU) were screened with the MGMT cDNA probe as follows: In 
each of 20 tubes, approximately 50,000 PFU were mixed with 600 µl of O.D.600 = 0.5 
PLKl 7 bacteria, incubated for 15 min at 37°C, and added to 3 ml of 48°C top agar 
(LB broth (Difeo), 0.7 % agarose (FMC). This mixture was poured on room 
temperature LB plates and incubated for 6 - 14 hours at 37°C, and then at 4°C for 
2 hr. Twenty bacterial plates each with 50,000 of these plaques were used in the 
primary library screening. 
In order to test the DNA from each plaque for hybridization to the MGMT 
cDNA, two nitrocellulose membranes were sequentially laid on the plates for 60 sec 
and then removed. Each filter was then submerged sequentially in denaturing 
solution (1.5 M NaCl/0.5 M NaOH, 2 min), neutralizing solution (1.5 M NaClf0.5 
M Tris-Cl pH 8.0, 5 min) and rinsing solution (0.2 M Tris-Cl pH 7.5/2X SSC). The 
filters were air dried on Whatman 3MM paper and the DNA was crosslinked to the 
filter by U.V. irradiation (Stratalinker, Stratagene). These duplicate membranes 
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were hybridized in a standard hybridization buffer (50 % formamide/10 % dextran 
sulfate/5X SSPE/EDTA buffer/1% SDS/250 µg per ml of denatured salmon sperm 
DNA/lX Denhardts solution) with a uniformly 32P-labelled MGMT cDNA. The 
filters were washed under stringent conditions [0.1 X standard saline phosphate 
(SSPE) (lX SSPE = 180 mM NaCl/10 mM sodium phosphate/I mM EDTA, pH 
7.0)/0.1% sodium dodecyl sulfate, 60°C for 5 min] in a Disc-Wisk washing system 
(Schleicher and Schuell, Keene, NH.), dried and autoradiographed (12 - 24 hr with 
intensifying screens). 
The autoradiograph was lined up with the original bacterial plate to 
determine which phage plaque corresponded to the positive signal on the 
autoradiograph. Identical hybridization signal on the autoradiograph of duplicate 
filters confirmed the specificity of the hybridization. Twenty plaques corresponding 
to positive signals were removed from the LB plate with the wide end of a pasteur 
pipette. Bacteriophage particles were eluted ( 4°C, overnight) into 100 µI - 1 ml SM 
buffer (1 L = 0.1 M NaCI/8.1 mM MgS04/50 mM Tris-HCl pH 7.5/.01% gelatin). 
The 20 positive phage populations isolated in this way were then purified through 
secondary and tertiary screening carried out in the same manner as the primary 
screening. 
The twenty clones were divided into four groups based on hybridization to one 
of four MGMT cDNA restriction fragments. The four cDNA fragments, listed 5' to 
3', are as follows: An 154 bp Pvull fragment spanning nucleotides 1 - 154 of the 
PCR amplified cDNA; a 207 bp Hinfl fragment spanning nucleotides 100 - 307; an 
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107 bp Hinfl/Hhal fragment spanning nucleotides 307 - 414; and an 137 bp Sstl 
fragment spanning nucleotides 584 - 721. 
Within each genomic clone, the MGMT gene fragment is internal to 17 bp T3 
and T7 promoter sequences which are in turn flanked by various restriction enzyme 
(RE) sites, including Notl sites. Cutting the entire recombinant DNA molecule with 
Notl therefore excises a DNA fragment containing the MGMT gene fragment 
flanked by the T3 and T7 promoter sequences. In order to arrange all of the 
isolated MGMT gene fragments into a continuous length of DNA covering the 
coding portions of the MGMT gene, the Notl-excised DNA from each different 
phage was analyzed by RE mapping. 
RE (BamHI, Hindlll and EcoRI,) maps of the twenty cloned MGMT gene 
fragments were generated as follows: The MGMT gene fragments were cut from 
phage vector DNA by complete digestion with Notl (5 U/µg DNA, Stratagene). The 
DNA products of the Notl digest were then partially digested in separate reactions 
with BamHI, Hindlll, or EcoRI, (0 U, .05 U, 0.5 U, 5 U, and 50 U, for 15 min, 37°C, 
(BRL)) and analyzed by Southern blot (as described below) with a 32P end-labelled 
T3 or T7 promoter primer (Stratagene). Rehybidization of these Southern blots 
with a 32P-labelled MGMT cDNA identified MGMT exons within each genomic 
clone. The number and position of restriction sites within each clone (the 
restriction map) were used to determine if the DNA fragments were overlapping or 
discontinuous with respect to their positions in the genome. Eight genomic clones 
with the minimal amount of overlap were then aligned to generate a discontinuous 
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map of the coding sequences of the MGMT gene. 
Analysis of MGMT Exons 
Four exons were identified in the genomic clones by Southern blot analysis 
with radiolabelled MGMT cDNA fragments (listed above). To facilitate sequencing 
of two MGMT exons, the genomic DNA fragments containing the exons were 
subcloned into plasmid vectors. A 4.8 kb BamHI/Hindlll fragment of genomic 
clone le containing the 5'-most exon (designated exon 2) of the cDNA used, was 
subcloned into the plasmid pGEM-3Zf (Promega, Madison, WI.), and a 2.8 kb 
Notl/Nael fragment (from genomic clone 7c) containing a second exon (designated 
exon 3) was subcloned into pBluescriptll SK+ (Stratagene). The resultant 
subclones were designated p5'BH and p7cNN, respectively. The exon regions of 
these subclones were sequenced with MGMT cDNA primers using the dideoxy 
sequencing method (Taq Track Sequencing System, Promega). Hybridization of a 
32P-labelled Hinfl/Hhal fragment of the MGMT cDNA (see above) to Southern blots 
of genomic clone Sb identified a third translated exon, designated exon 4. 
Nucleotides complementary to the MGMT cDNA within the 3'-most exon were 
identified in cloned genomic DNA by PCR amplification (as described above) using 
primers complementary to the 3' end of the MGMT cDNA (primer 1, 
complementary to nucleotides 590-610, primer 2, complementary to nucleotides 776-
755). This region was designated exon 5. 
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Generation of Intron Specific Probes 
An intron 1 region, 5 kb 5' of exon 2, was derived from an EcoRI digest of 
genomic clone ld. Following electrophoresis of the digestion products through a 
0.5% low-melt agarose (FMC) gel, a 3.8 kb EcoRI fragment was cut from the gel and 
recovered by centrifugation (5 min, 12,000 x g) through siliconized glass wool 
(Alltech, Deerfield, IL.). A 3.8 kb EcoRI fragment, 10 kb 3' from exon 3 was used 
as an intron 3-specific probe. An Eagl fragment, 4 kb 3' of exon 5, was used as a 
probe to examine methylation at the 3' end of the MGMT gene. Approximately 25 
ng of the intron fragments were used as templates for generating intron-specific 
probes by random priming. 
Identification and Sequencine of CpG Islands within Genomic Clones 
Potential CpG islands within each MGMT genomic clone were identified by 
RE mapping as described above except using CpG island-sensitive RE (BssHII, 
Eagl, Nael, Nari, Notl, Smal, Sacll). Restriction sites for CpG island-sensitive REs 
are rare in bulk DNA, but occur relatively frequently in CpG island DNA (Lindsay 
and Bird, 1987). 0.5-3.0 kb clusters of the CpG island-sensitive RE sites thus 
identified potential CpG islands within the 12-23 kb MGMT gene fragments. Three 
MGMT gene regions containing clusters of these RE sites (designated region 1, 2, 
and 3), all within one genomic clone (7c), were subcloned and sequenced to 
determine if these regions had CpG island characteristics. The 5' - most region, 
containing part of exon 3, was excised from the genomic clone 7c by digestion with 
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Notl and Nael. The 2.6 kb Notl/Nael fragment was then ligated into Notl/Smal-
cut pBluescriptIISK + plasmid (Stratagene) in a 10 µl ligation reaction containing 
o.7 units of T4 DNA ligase, lX ligase buffer, and an approximately 3:1 molar ratio 
of insert to vector DNA. Following incubation at 14°C for 12 hr, the reaction was 
diluted 1:5 with 10 mM Tris-HCL/1 mM EDTA pH 8.0, and 1 and 3 µl aliquots of 
the diluted reaction were used to transform competent bacteria (DH5a) according 
to the manufacturer's protocol (BRL). 9, 90, and 900 µl aliquots of transformed 
bacteria were then spread onto separate LB bacterial plates containing 0.5 mM 
IPTG (Fisher), 40 µg/ml X-Galactose (Promega), and 100 µg/ml ampicillin (Sigma). 
Several white bacterial colonies were removed from the plates and used to inoculate 
LB broth containing ampicillin. The inoculated LB broth was subsequently placed 
in a 37°C shaking incubator (250 cycles/min.) for 8 -12 hr. 50 - 100 µg of the 
recombinant plasmid DNA (p7cNN) was recovered from the transformed bacteria 
(Quiagen minicolumn). To facilitate sequencing of relevant areas, p7cNN was 
digested with Eagl, which removed a 1.2 kb Notl/Eagl fragment, and religated to 
generate the 1.6 kb Eagl/Nael insert in p7cEN. 
A 4.7 kb EcoRI fragment (middle of 7c) and 3.8 kb EcoRI fragment (3' in 7c) 
of genomic clone 7C, which also contain clusters of the recognition sites for CpG 
island sensitive restriction enzymes, were subcloned in a similar manner into EcoRI 
digested pBluescript plasmid. To facilitate sequencing of regions of interest, these 
subclones were further subcloned as 3.1 kb and 1.6 kb Smal/EcoRI fragments (for 
the 4.7 kb middle subclone) and as 2.4 kb BssHII/Notl fragment (for the· 3.8 kb 
subclone). A nucleotide sequence for each subclone was determined using the 
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dideoxy sequencing method (Taq Track, Promega). 
Northern Blot Analysis of MGMT mRNA 
Total cellular RNA was isolated from each glioma cell line by a guanidinium 
isothiocyanate lysis procedure (Chirgwin,n_fil., 1979). Twenty µg of RNA from each 
glioma cell line was denatured by incubation at 50°C for 1 hr in a 21 µl reaction 
composed of 3 µl of 7 M glyoxyl, 10.5 µl DMSO, 2.1 µl 0.1 M NaH2P04 pH 6.8 and 
5.4 µl RNA. The denaturing reaction was then briefly cooled on ice before addition 
of 4 µl loading buffer ( 40'fo sucrose/0.25% bromophenol blue (BPB) ), Following 
electrophoresis (100 V, 4.5 hr) in a 1% agarose gel (1.4 g agarose/140 ml 10 mM 
NaP04 pH 6.8) the RNA was transferred to a nylon membrane by capillary 
blotting. The membrane was then soaked sequentially in 50 mM NaOH for 15 sec 
and lX standard saline citrate (lX SSC = 0.15 M NaCl/15 mM sodium citrate, pH 
7.0), 0.2 M Tris-HCl pH 7.5 for 30 sec. The RNA was fixed to the membrane by UV 
crosslinking (Stratalinker) once the membrane had air dried. To confirm that the 
RNA was intact, the 28s and 18s rRNA bands were visualized on the filter under UV 
light. The membrane was prehybridized in standard prehybridization solution (same 
solution as for library screening) for 4 hr at 42°C. Following addition of 32P-
labelled MGMT cDNA probe, the membrane was washed initially in lX SSPE/0.1% 
SDS, 25°C for 15 min and then at 60°C, O.lX SSPE/0.1% SDS for 6 min in a Disc 
Wisk apparatus. Relative hybridization of the probe to glioma RNA was determined 
with a Betascope 603 blot analyzer (Betagen). Additionally, the membranes were 
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autoradiographed for 4-8 days. 
The membranes were subsequently stripped of bound probe by submersion in 
a boiling solution composed of 1 % SDS, 10 mM Tris pH 8, 1 mM EDTA for 30 
min. After drying, the membranes were prehybridized and hybridized with a 
radiolabelled histone H3.3 cDNA probe. Hybridization of the probe to histone H3.3 
mRNA was visualized by autoradiography. 
MGMT Protein Assay 
The relative amount of MGMT DNA repair activity in each glioma cell line 
was determined by an in vitro assay which measures the extent to which glioma cell 
sonicates repair methyl group adducts at 06-guanine within a 32P-end-labelled 18 bp 
DNA substrate (Wu, et al., 1987; Futscher, et al., 1989). 
2-5X106 cells from each glioma cell line were centrifuged and the cell pellet 
was washed twice with cold lX phosphate buffered saline (lX PBS = 0.137 M 
NaCl/2.68 mM KCl/10.14 mM Na2HP04/1.76 mM KH2P04, pH 7.4). The cells 
were resuspended in 400 µl ice cold assay buffer (50 mM Tris pH 8.0/1 mM 
EDTA/5 mM dithiothreitol/5% glycerol) and sonicated on ice in 12-5 sec bursts 
(with 5 sec off time between each burst to prevent the sonicator probe from heating 
the cell sonicates) of 0.3 relative output with a Virsonic cell disrupter (Virsonic). 
Following centrifugation (12,000 RPM, 30 min) the protein concentrations of the 
supernatants were determined spectrophotometrically. The extent of absorption of 
595 nm light in a 1 ml solution composed of 1 or 2 µl aliquots of the supernatant 
34 
from each glioma cell line, 200 µl protein assay dye reagent (Biorad, Richmond, 
CA), and ddH20 was measured spectrophotometrically and then converted to µg of 
protein/ µl of glioma sonicate by a Bradford protein assay program. The µl 
amounts of sonicate equaling 5, 10, and 25 µg protein for each cell line were then 
incubated separately in 150 µl reactions with 0.2 pmol of radiolabelled 18 hp 
MGMT substrate at 37°C for 2 hr. The labelled DNA substrate was then extracted 
three times with phenol/chloroform:isoamyl alcohol (24:1), once with 
chloroform:isoamyl alcohol and then precipitated (-70°C, 1 hr) with 1/10 vol. 3M 
sodium acetate pH 5.2, 3 vol 100% ethanol. After centrifugation (12,000 RPM, 30 
min) the DNA was washed with 70% ethanol and lyophilized. The lyophilized DNA 
was resuspended in 17 µl ddH20 and incubated with 10 units of Pvull (BRL) for 1 
hr at 37°C. Three unreacted control samples were incubated with no RE, Pvull, or 
Haelll. The digestion reactions were then terminated by adding 9 µl of 96% 
formamide dye (96% formamide/lmM EDTA/0.1% BPB/0.1% xylene cyanol). After 
a 5 min incubation at 95°C and a quick cooling on ice, 10 µl of each sample was 
electrophoresed on a 20% denaturing polyacrylamide gel for 1.5 hr. The relative 
amount of radiolabelled, cleaved to uncleaved DNA substrate was then determined 
with a Betascope blot analyzer. 
autoradiographed for 2-3 hr. 
DNA Isolation 
Additionally, the gels were directly 
Genomic DNA was isolated from 10 - 20 X 106 cells of each glioma cell line. 
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The cells were centrifuged (2200 RPM, 5 min), washed twice with cold lX PBS pH 
7.4, and lysed in cell lysis buffer [17 mM NaHCOi27.6 mM Na2C03/1 mM EDTA 
pH 8.0/0.4% N-lauroylsarcosine/.024% proteinase K (Merck)]. Following 
incubation at 37°C for 4 - 7 hr, DNA was recovered by three 
phenol/chloroform:isoamyl alcohol (24:1) extractions, one chloroform:isoamyl 
alcohol extraction, and an ethanol precipitation (0.2 volumes 11 M ammonium 
acetate/2.5 volumes 95% ethanol). The DNA pellet was washed twice in 70% 
ethanol, resuspended in 4 ml of ddH20, and treated with 40 µg of RNAse for 30 min 
at 37°C. The extraction, precipitation and ethanol washing steps were repeated, 
followed by DNA resuspension in 400-800 µl 10 mM Tris-HCl/1 mM EDTA, pH 8.0. 
Analysis of the Methylation Status of the Body of the MGMT Gene 
Analysis of the methylation status of the body of the MGMT gene in the 
glioma cell lines was accomplished by Southern blot analysis of genomic DNA 
digested with the methylation sensitive and insensitive isoschizomers Hpall and 
Mspl, respectively (BRL). Ten µg of genomic DNA from each cell line was 
incubated (37°C, 6-8 h) in a 200 µl reaction containing lX RE buffer and Hpall (7-
10 U/µg DNA) or Mspl (7-10 U/µg DNA). To control for completion of digestion, 
aliquots (20 µl) of the final reaction mixture were removed from each digestion 
reaction and incubated with a uniformly 32P-labelled MGMT cDNA. Generation of 
the expected restriction fragment pattern of the labelled MGMT cDNA, as assessed 
by autoradiography of these control samples following electrophoresis and transfer 
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to a nylon membrane, reflected complete digestion in the primary digests. DNA 
from the primary digests was then extracted, precipitated, and resuspended in 20 
µl ddH20. For analysis of intron 1 and the 3' end of the gene, the DNA samples 
were further digested with EcoRI (10 U / µg) for 6 hr. Equal amounts (10 µg) of 
DNA from each digest were electrophoresed (15-20 V, 24 hr) through 0.7 % agarose 
gels. The DNA was then depurinated by soaking the gel in 0.25 M HCl for 15 min. 
After rinsing the gel in dH20, the DNA was denatured by soaking the gel in 0.5 M 
NaOH/1.5 M NaCl for 30 min. Following a brief dH20 rinse, the gel was submerged 
in neutralization solution (0.5 M Tris pH 7.5/3 M NaCl) for 45 min. DNA was then 
transferred from the gel to a nylon membrane by capillary blotting in lX SSC. 
Following the transfer, the membrane was submerged in 0.4 N NaOH for 45 sec, 
and then in 0.2 M Tris/2X SSC for 90 sec. After allowing the membrane to dry at 
room temperature, the DNA was covalently bound to the membrane by UV 
crosslinking (UV Stratalinker). The membrane was prehybridized and then 
hybridized to various MGMT intron specific probes in a manner analogous to that 
described for northern blots. 
Ouantitation of Methylation at an MGMT Intron 1 Site 
The percent of MGMT gene alleles within each glioma cell line that are 
methylated at an intron 1 site, located 5 kb 5' of the translation start site, was 
determined by Southern blot analysis of EcoRI digested glioma cell line DNA 
hybridized with the 3.8 kb EcoRI intron I probe described above. DNA (10 - 20 µg) 
..,. 
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from each glioma cell line was digested with 75 U EcoRI for 6 hr at 37°C and then 
overnight with an additional 100 U EcoRI. Relative hybridization of the 
radiolabelled intron I fragment to the 3.8 kb (unmethylated) and 4.5 kb 
(methylated) EcoRI digestion products was assessed with a Betascope 603 blot 
analyzer. The percent methylation of the EcoRI site was calculated as the ratio of 
4.5 kb fragments to 3.8 + 4.5 kb fragments multiplied by 100. The relationship 
between percent methylation and MGMT mRNA levels was examined by linear 
regression analysis (SigmaPlot5). 
linker-Mediated PCR Analysis CLMPCRl of MGMT Promoter Methylation 
For methylation analysis by LMPCR, nuclei were isolated from the glioma cell 
lines according to a method described by Wijnholds, et al., 1988. 1X107 - 1X108 
glioma cells were washed with ice-cold lX PBS, centrifuged (2300 RPM, 5 min) and 
resuspended in 5 ml ice-cold buffer A (0.3 M sucrose/60 mM KCl/15 mM NaCl/60 
mM Tris-Cl pH 8.0/0.5 mM spermidine/0.15 mM spermine/2 mM EDTA). 5 ml 
cold buffer A with 1 % Nonidet P40 (NP-40, Sigma) was added and the samples were 
incubated on ice for 5 min. The sample was centrifuged (lOOOXg, 5 min) and the 
nuclei pellet was washed with 15 ml of cold buffer A. DNA was isolated from the 
nuclei according to Saluz, et al., 1987 by resuspending the nuclei in 5 ml of buffer 
B (150 mM NaCI/5 mM EDTA pH 7.8), adding 5 ml of room temperature buffer 
C [20 mM Tris-Cl/20 mM NaCI/20 mM EDTA/1% SDS/600 µg/ml proteinase K 
(Sigma)] and incubating the samples at 37°C for 3 hr. RNase was added (100 
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µg/ml) and the samples were incubated at 37°C for 1 hr. DNA was extracted and 
precipitated as described above and then cut with EcoR I (5 U/µg) to reduce 
viscosity. Following extraction and precipitation, the DNA was dialyzed for 20 hr 
in 3 changes (at 4 hr, 18 hr and 19 hr) of 4 L ddH20. Forty µg of DNA was 
cleaved with genomic sequencing chemicals as described by Maxam and Gilbert, 
1980. For sequencing of plasmid DNA, 1 µl of BamH I cut plasmid (containing the 
1.2 kb MGMT promoter) was added to 40 µg of dialyzed, sheared salmon sperm 
DNA. 
The LMPCR protocol was based on the method described by Pfeifer, .rt_fil., 
1989 and consisted of extension, ligation and amplification steps. All DNA primers 
for LMPCR were gel purified except an 11 nt linker primer (see below). For 
extension reactions, a 15 µl reaction containing 5.0 µg of cleaved genomic DNA, 0.5 
pmol of the extension primer (for promoter region I; 5'-
CGGGCCATITGGCAAACTAAG-3', corresponding to MGMT promoter nt 655-675, 
for region II; 5' -AGGCACAGAGCCTCAGGCGGAAGCT -3', corresponding to nt 805-
823), and lX sequenase buffer [United States Biochemical (USB)] was incubated 
at 95°C for 3 min, and then 60°C for 30 min. The reaction was cooled on ice and 
7.5 µl of dNTP mix [final concentration in mix was 0.062 mM dGTP/0.188 mM 7-
deaza dGTP/0.2 mM each of dCTP, dATP, dTTP (Pharmacia)], 0.5 µl of 0.5 M 
MgC12, 0.95 µl of 1 M dithiothreitol and 1.5 µl of a 1:4 dilution (in TE pH 8.0) of 
Sequenase version 2.0 (USB) were added. Following primer extension (48°C, 15 
min), the reactions were cooled on ice, 6 µl of cold 300 mM Tris, pH 7. 7 was added, 
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and the Sequenase was heat inactivated (67°C, 15 min). The reaction was cooled 
on ice. In ligation steps, a double stranded DNA linker (see below) was ligated to 
the extension products by addition of 45 µl of a ligation mix (13.33 mM MgC12/30 
mM DTT/1.66 mM ATP/83.3 µg BSA/100 pmoles linker DNA and 3 U/reaction T4 
DNA ligase (Promega)) to each reaction. After ligation (18°C, 12-16 hr) the 
reaction was heated (70°C, 10 min) and then cooled on ice. The DNA was 
precipitated (along with 10 µg yeast tRNA), washed with 70% ethanol, lyophilized 
and resuspended in 67 µl ddH20. The ligated DNA was then incubated in a 100 µl 
reaction containing 10 µl of dNTP mix (0.067 mM dGTP/0.133 mM 7-deaza 
dGTP /0.2 mM each of dATP, dCTP, dTTP), lX Stoffel fragment buffer, 2.5 mM 
MgC12, 10 U Stoffel fragment ofTaq Polymerase (Perkin Elmer Cetus), and 10 pmol 
each of the longer (25 mer) linker primer and a nested gene-specific primer (for 
promoter region 1; 5'-AGGCACAGAGCCTCAGGCGGAAGCT-3', nt 674-698, for 
promoter region 2; 5'-TGGGCATGCGCCGACCCGGTC-3', nt 841-861)(13) and 
amplified by PCR (5 min, 95°C followed by 18 cycles of 95°C for 1 min, 66°C for 2 
min and 76°C for 3 min with a 5 sec extension of the 76°C step after each cycle and 
10 min at 76°C after cycle 18). 32P labelled PCR products were generated through 
two additional PCR cycles with a second nested end-labelled primer (promoter 
region I; 5'-AGGCACAGAGCCTCAGGCGGAAGCTGGGA-3', nt 674-702, promoter 
region 2; 5'-TGGGCATGCGCCGACCCGGTCGGG-3', nt 841-864). Seven µl of a 
mix containing lX Stoffel buffer, 2.5 mM MgC12, 0.1 U Stoffel fragment/ µl and 4.0 
pmol of the 32P labelled primer (see below) was added to the amplification reaction. 
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Following two cycles of PCR (same parameters as above except annealing was at 
67°C and extension at 77°C), the DNA was extracted, precipitated, and resuspended 
in 10 µl of LMPCR dye (80% formamide/45 mM Tris base/45 mM boric acid/1 mM 
EDTA/.05% BPB/.05% xylene cyanol). Five µl of the sample was electrophoresed 
(55 Watts, 2 • 3 hr) through a 6 % denaturing polyacrylamide gel. Radiolabelled 
amplification products were detected by autoradiography (6-18 hr exposure). 
In Vivo Dimethylsulfate CDMSl Footprint Analysis of the MGMT Promoter 
Glioma cells were treated with 0.1 % DMS in fresh media (37°C, 2 min) and 
then washed three times with lX PBS. DNA was then isolated, resuspended in lM 
piperidine and heated for 30 min at 95°C. Following precipitation, the DNA was 
washed twice with 80 % ethanol and lyophilized overnight. The DNA was 
resuspended in ddH20 and 5 µg was analyzed by linker-mediated PCR as described. 
Gel Purification and Radiolabelin& of LMPCR Primers 
DNA Primers were gel purified according to published protocols (Ausubel, fil. 
al., 1992). 100-120 µg of each primer was diluted 2-fold in 2X formamide loading 
buffer [lX TBE (lX TBE = 89 mM Boric Acid/89 mM Tris base • 2.0mM 
EDTA)/90% deionized formamide/0.5% BPB], heated to 95°C for 5 min and placed 
on ice. The entire sample (80 - 120 µl) was loaded on a 15 % denaturing 
polyacrylamide gel using lX TBE for running buffer. The samples were 
electrophoresed (300-500 V, 2-3 hr) after which the gel was removed from the 
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apparatus and wrapped in saran wrap. The gel was placed over a thin-layer 
chromatography plate with flourescent indicator and the DNA was visualized with 
a U.V. lamp (U.V. shadowing). A gel slice containing the appropriately sized primer 
DNA was removed, crushed, and the DNA was eluted (37°C, overnight, shaking 
incubator) from the acrylamide in 0.3 M sodium acetate, pH 7.5. The primer DNA 
was extracted once with phenol and once with chloroform before ethanol 
precipitation. The primers were end-labelled in a reaction containing 25 - 35 pmol 
primer (1 pmol/µl), 300 - 500 µCi gamma-32P-ATP ( > 5000 Ci/mmol), lX T4 
polynucleotide kinase buffer (Promega) and 0.05 U polynucleotide kinase/ µl. The 
reaction was incubated for 30 - 60 min at 37°C, 2 min at 95°C and cooled on ice. 
Unincorporated gamma-32P-ATP was removed from the reaction by centrifugation 
(4 min, 3800RPM) through a G-25 sephadex column (5 Prime - 3 Prime) 
equilibrated with 3 ml of ddH20. 
Linker Annealine 
The linker primer sequences and annealing reactions were as described by 
Mueller and Wold, 1989. The 25 nt linker primer was 5' 
GCGGTGACCCGGGAGATCTGAATTC - 3' and the 11 nt linker primer was 5' -
GAATTCAGATC - 3'. The primers were annealed in a 300 µl reaction containing 
6000 pmoles of each primer and 250 mM Tris-Cl pH 7. 7. The reaction was heated 
to 95°C for 5 min, centrifuged briefly and incubated at 70°C for 10 min. The 
reaction was cooled to 25°C over 2 hr (2°C decrease every 5 min) and incubated at 
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25°C for 1 hr. After cooling to 4°C (2°C decrease every 5.5 min), the reaction was 
incubated at 4°C for 12 hr and stored at -20°C. 
Analysis of Restriction Enzyme Accessibility to the MGMT Gene within Nuclei 
Glioma cells were washed twice with cold lX PBS and harvested by scraping 
into Sml of fresh lX PBS. The cells were centrifuged (5 min, 3500 RPM) and then 
resuspended in 1.0 ml of cold RSB buffer (10 mM Tris,pH 8.0/10 mM NaCl/3 mM 
MgC12) and .05 % NP-40 to disrupt the cell membranes. Nuclei were pelleted by 
centrifugation (12,000RPM, 4 sec), washed twice in lX RE buffer and resuspended 
in 350 µl fresh lX RE buffer. Nuclei equivalent to 30 µg of DNA were incubated (10 
min, 37°C) with either Mspl (20 - 400 U), Avail (16 U), Alul (6 - 40 U), or DNAsel 
(0.6 - 60 U). DNA was then isolated from the nuclei, precipitated, and resuspended 
in ddH20 (1.0 µg DNA/µ1). For the promoter studies, 5.0 µg of DNA from the 
nuclei digests was analyzed by LMPCR as described above, except autoradiograph 
exposures were 2-5 hr, with intensifying screens. For analysis of RE accessibility to 
the body of the gene, DNA was isolated from the nuclei, precipitated, and 
resuspended in 16 µl dH20 + 2 µl lOX EcoR I buffer. All DNA samples were 
digested with 100 U EcoRI (2 hr, 37°C), one sample with EcoRI and Mspl, (10 
U/µg) and one with EcoRI and Hpall (10 U/µg). 10 µg of each digest was then 
analyzed by Southern blot as described above. 
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Gel Shift 
To prepare protein extract for gel shift analysis 5 - 10Xl06 cells (glioma cells 
and for control reactions, HeLa cells) were centrifuged (12,000 RPM, 5 sec), the 
supernatant was discarded and the cells were quickly frozen in liquid nitrogen. The 
cells were resuspended in 5 volumes buffer C (25 % glycerol/420 mM NaCI/1.5 mM 
MgC12/0.2 mM EDTA/up to 100 ml with ddH20/20 mM Hepes pH 7.9/0.5 mM 
DTT/0.5 mM PMSF), centrifuged (100,000xg, 5 min), and the supernatant pipetted 
into a new tube. Ten µg cell extract (measured spectrophotometrically, as described 
for MGMT assay) was incubated with 0.1 ng (1 ng/µg) of a double stranded, 32P-
end-labelled, 22 hp DNA fragment (10,000 - 50,000 CPM/ µl containing a single Spl 
binding site (Spl oligonucleotide, Promega) in a 25 µl reaction containing 1.0 µl 
poly(dl)poly(dC)(0.5 µg/µl), 1.0 µl of BSA (10 mg/ml), and lX binding buffer (lX 
= 10 mM Tris pH 7.5/50 mM NaCl/1 mM EDTA/5% glycerol/1 mM DTT). For 
the specific competition experiment, an 100-fold excess unlabelled Spl 
oligonucleotide was added 20 min prior to addition of HeLa cell extract. A 100-fold 
excess unlabelled heat shock factor oligonucleotide (non-specific competitor)(5'-
CTAGAAGCTTCTAGAAGCTTCTAG-3') was added to a separate tube prior to 
addition of HeLa cell protein extract. Each reaction (HeLa controls and glioma 
samples) was incubated for 20 min at 25°C, 2.5 µl dye (50 % glycerol - 0.2 % BPB -
0.2 % xylene cyanol) was added and the sample was electrophoresed (120 - 160 V, 
2 - 3 hr) through a 4 % polyacrylamide gel. The gel was autoradiographed for 1 -
5 hr. 
CHAPTER IV 
RESULTS 
Analysis of the MGMT Gene Codina= Sequences 
To examine the organization of the human MGMT gene coding sequences, a 
genomic library was screened with an MGMT cDNA probe. Twenty positive clones 
isolated after primary screening were purified to homogeneity through secondary 
and tertiary screening. The primary, secondary and tertiary screenings of a 
representative clone (7c) are shown in fig. 1. The clones were divided into four 
groups based on hybridization to one of four cDNA restriction fragment probes 
(fig.2). Two MGMT genomic clones (lb/2e) hybridized to cDNA fragments 3 and 
4, suggesting that these clones may contain two or more exons, one common to 
group 3 clones and one common to group 4. Each clone was analysed for BamHI, 
Hindlll, and EcoRI restriction sites, and then aligned with the other clones. Eight 
of these clones with minimal overlap were used to generate a preliminary map of 
the coding sequences of the MGMT gene consisting of four translated exons and 
spanning > 80 kb (fig.3) ( exon 1, not shown here, is nontranslated (Harris, et al., 
1991). Comparison of the nucleotide sequence of the S' most exon, derived from 
sequencing genomic subclone pS'BH (fig.3), to the published cDNA sequences (Tano, 
.ru.i., 1990) demonstrated that the 135 bp comprising this exon was contiguous with 
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Figure 1. Primary, secondary and tertiary screening of a human genomic library 
with a radiolabeled MGMT cDNA. Approximately 1X106 clones were tested for 
hybridization to the 730 hp MGMT cDNA probe (which includes all the protein 
coding portions). Tuenty positive clones were identified by the presence and 
identical location of positive signal on duplicate filters (from the same LB plate). 
A LB plug containing each of these clones corresponding to a positive signal (eg. 
arrow in 1° panel) was removed from the plate, eluted in 1 M SM buffer, and then 
purified through secondary (2°) and tertiary (3°) screening. Every phage plaque 
present on the tertiary screening plates hybridized to the MGMT cDNA probe, 
indicating that these phage populations contained MGMT gene fragments and were 
purified to homogeneity. 
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Figure 2 Relative placement of genomic clones into one of four groups based on 
hybridization to MGMT cDNA fragment probes. Tuo µg of each genomic clone 
were cleaved with Notl (10 U for 1 hr) and analyzed by Southern blot, as described, 
with sequential hybridization to each of the four cDNA fragment probes (open bars 
with vertical lines). Positive hybridization to genomic clones 2e and lb was seen 
with the two 3' probes. 
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Figure 3. Restriction enzyme map of the coding sequences of the human MGMT 
gene. A genomic library derived from a human fibroblast cell line DNA was 
screened with a 32P-labelled MGMT cDNA that spanned nucleotides 70-777 (which 
includes the entire protein coding region). Eight positive clones analyzed by 
restriction enzyme mapping with BamHl(B), EcoRl(E), and Hindlll(H), were 
aligned to form a discontinuous map of the gene. Exons (open triangles) within two 
genomic subclones, p5'BH and p7cNN, were sequenced and compared to the 
corresponding cDNA nucleotides. Nucleotides complementary to cDNA sequences 
590-776 were identified within genomic clone llb (exon 5) by PCR amplification 
with primers defining this cDNA region. Gaps in the map represent intron regions 
of unknown size. The positions and length of the intron probes used for 
methylation analysis are indicated by solid lines located below the subclones. The 
dashed line immediately 5' of the intron 3 probe indicates the position of a 4. 7 kb 
EcoRI probe also used to examine methylation. 
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exon 1 in the MGMT cDNA. This region was therefore designated exon 2. Exon 2 
contains approximately 12 nontranslated nucleotides followed by the translation 
start site and nucleotides encoding amino acids 1 through 41. Exon 3 encodes > 
41 amino acids, beginning with amino acid 42, and is followed by two 3' exons which 
were separated by an intron of less than 7 kb. The first of these two exons ( exon 
4) was identified by hybridization of a 3' MGMT cDNA fragment to genomic clone 
Sb DNA. The 3'-most exon (exon 5), analysed by PCR amplification of genomic 
clone llb DNA with 3' MGMT cDNA specific primers, spans > 185 hp and extends 
into the 3' nontranslated region. These genomic clones include all translated exons 
and span the body of the MGMT gene (Nakatsu, et al., 1993). 
Map_pina= of CpG Island Sensitive RE Sites within MGMT Genomic Clones 
Because the MGMT cDNA is very GC rich and contains and overabundance 
of CpGs, it is possible that one or more of the exons which comprise the cDNA 
sequence may be part of a CpG island. In order to identify potential CpG islands 
within the MGMT gene, the sites for CpG island-sensitive RE were mapped within 
genomic clones from each MGMT gene region. The recognition sites for CpG island 
sensitive RE are entirely composed of cytosines and guanines and contain one or 
more CpG dinucleotide. These sites are therefore rare in bulk DNA, but occur 
relatively frequently in CpG island DNA (Lindsay and Bird, 1987). Clusters of 
three or more of these sites within 0.5 - 3.0 kb indicate the location of potential 
CpG islands. MGMT genomic clones from each of the four groups were analyzed 
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Figure 4. Map of sites for CpG island-sensitive RE in genomic clone 7c. The 
position of sites for BssHII (B), Eagl (E), Nael (N), Notl (Nt) Saeli (Sc) and Smal 
(S) were determined within clone 7c DNA by RE mapping. Subclones containing 
each of the three clusters of the CpG island-sensitive RE sites are shown directly 
below the region of 7c from which they were derived. Ee, EcoRI site, and (open 
triangles), position of exon 3. Sequence data from each of the subcloned regions is 
shown in table 1. 
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for potential CpG islands by mapping the restriction sites for the CpG island-
sensitive REs BssHII, Eagl, Nari, Nael, Notl, Smal, and Sacll. Although most of 
the MGMT genomic clones contained only a few of these sites and generally not in 
clusters, three obvious clusters of these sites were found within genomic clone 7c 
(fig. 4). The 5' most cluster was associated with exon III and the middle and 3' 
clusters are contained in intron 3. DNA containing each cluster of sites was 
subcloned and partially sequenced to determine if these regions have the high GC 
content ( > 50%) and overabundance of the dinucleotide CpG [a ratio > 0.6, 
calculated from the equation ((#CpG/#G x #C) x #nucleotides analyzed)] 
characteristic of CpG islands (Gardiner-Garden and Frommer, 1987). The results 
of the sequence analysis are shown in table 1. All three regions analyzed did have 
an overabundance of CpGs relative to bulk DNA and a GC content between 40-60% 
The overabundance of CpGs however, was clearly below the frequency found in CpG 
islands. Analysis of these sequences in segments of 125 - 565 nt, rather than as a 
whole, revealed small but CpG-rich regions of the MGMT gene. The significance 
of small CpG-rich segments of DNA is unknown, but because of the high content 
of CpGs the methylation status of these regions may be relevant in a potentially 
methylation-mediated establishment or maintenance of glioma MGMT gene 
expression. 
Analysis of MGMT Expression in 10 Human Glioma Cell Lines 
MGMT expression in each glioma cell line was determined at the mRNA and 
I 
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Table 1. Analysis of GC content and CpG ratios in regions cf the 
MGMT gene that contain a cluster of recognition sites for CpG island 
sensitive restriction enzymes 
I I 
DNA Region : Nucleotides 
I 
%GC ! CpG ratio• 
! Analyzed I I I 
CpG island DNA 500-2000 >50% >0.60 
Region 1- exon 3 1600 54.0% 0.41 
1.6kb Eag-Nae (1-1600) 
565 57.2 0.53 
(1035-1600) 
536 50.7% 0.35 
. (5' 1-536) 
Region 2- intron 3 160 58.0 0.48 
4.7kb Eco-Eco (5' 1-160) 
994 ;~; ~~,:~ 53.0% 0.32 
(3 '1-994) 
150 58.4 0.53 
(3' 1-150) 
880 43.0% 0.30 
(5' 1-180) 
Region 3- intron 3 490 49.3 0.45 
3.8kb Eco-Eco (5' 390-880) 
765 53.9% 0.29 
(3' 1-765) 
150 63.0% 0.46 
(3' 1-150) 
Bulk DNA I - II <40.0% I 0.20 I 
• CpG ratio calculated from the equation: LpU ratio = l #LpU dmucleotJ des/ (#C X 
#G)] X # nucleotides analyzed. 
Note: Region 2 and 3 were sequenced inward from both ends of the subclones. In the 
Nucleotides Analyzed column the sequences are therefore denoted as 5' or 3' with respect . 
to their ends within the MGMT gene. 
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Figure 5. Northern blot analysis of MGMT mRNA levels in 10 glioma cell lines. 
Twenty µg of total cellular RNA from MGMT+ and MGMT- glioma cell lines was 
denatured, electrophoresed, transferred to a nylon membrane and hybridized with 
a 32P-labelled MGMT cDNA (top panel). Following MGMT probe removal, the 
membrane was hybridized with a histone H3.3 cDNA probe (bottom panel). The 
membranes were washed under stringent conditions (60°C, 7 min, 0.1 % SDS/O.lX 
SSPE in a circulating water bath) and exposed to x-ray film (4-7 days) in the 
presence of intensifying screens. 
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protein levels. 
The relative amount of MGMT mRNA in each glioma cell line was measured 
by northern blot analysis with an MGMT cDNA probe. The results of a 
representative northern blot, seen in figure 5, demonstrated that MGMT mRNA was 
present in 1'98, U138, SF763, SF767, NAT, U373, and HS683 but was not detectable 
in Al235, CLA, or CRO (top panel). The amount of MGMT mRNA within each cell 
line was quantitated and then expressed as the average of two independent northern 
blots (Table 2). In order to ensure that the lack of detectable MGMT mRNA in 
Al235, CLA and CRO was not simply due to degraded RNA in these samples, the 
northern blots were rehybridized with the cDNA complementary to the histone H3.3 
gene. Histone H3.3 mRNA should be present in all the cell lines as histone H3.3 
gene expression is constituitive and cell cycle independent (Wellman, et al., 1987). 
Figure 5 (bottom panel) shows that histone H3.3 mRNA was present in the RNA 
from all the cell lines indicating that the lack of detectable MGMT mRNA in A1235, 
CLA, and CRO was not due to degraded RNA in these samples. 
The relative levels of MGMT activity were determined from an in vitro assay 
that measures the ability of glioma protein extracts to remove a methyl-group 
adduct from the 0-6 position of guanine in an 18 hp DNA substrate (Wu, et al., 
1987; Futscher, et al., 1989). Five, ten, or twenty-five µg of protein (lanes 1,2,3 of 
each triplet, respectively) from glioma cell sonicates were incubated with a 
radiolabelled 18 bp DNA fragment that contains a methyl group adduct at 0 6-
guanine within a Pvull RE site (CAGCTGme). The amount of MGMT activity in 
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Figure 6. In vitro assay of MGMT activity within each glioma cell line. Five, ten or 
twenty-five µg of glioma cell sonicates were incubated (2 hr, 37°C) with a 
radiolabelled 18 hp DNA substrate containing a methyl-group adduct at the 0-6 
position of guanine within a Pvull recognition site. Unreacted 18 hp probe was 
incubated with Pvull (P), Haelll (H) or no enzyme (C). The DNA from control and 
glioma cell sonicate-reacted samples was extracted, precipitated, and resuspended 
in lX Pvull buffer (except the Haelll control sample (H) which was resuspended 
in lX Haelll buffer). The DNA was digested with Pvull (1 hr, 37°C), 9 µI of 95% 
formamide dye was added and one third of the reaction was electrophoresed (1 - 2 
hr, 26 mA) through a 20% denaturing polyacrylamide gel. The gel was 
autoradiographed for 1 - 3 hr in the presence of intensifying screens. 
Table 2. Quantitation of MGMT mRNA and MGMT activity in 
ten glioma cell lines 
Glioma Cell MGMT MGMT 
Line mRNA levels Activity 
(% of T98) (%of T98) 
T-98 100% 100% 
SF-763 78.8 121 + 15 
U-138 76.8 96 + 12 
SF-767 61.6 110 + 19 
Nat 48.5 79 + 12 
U-373 38.4 38 + 2 
HS-683 33.3 38 + 9 
A1235 0 <1 
Cla 0 <1 
Cro 0 <1 
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Table 2. Quantitation of MGMT mRNA and MGMT activity in ten glioma cell lines. 
3MGMT mRNA levels in each cell line were quantitated (Betascope 603 blot 
analyzer) from two independent northern blots, averaged, and expressed as the 
percent of '1'98 MGMT mRNA level. Within each cell line the average difference 
between duplicate experiments was < 12%. bValues for MGMT activity, determined 
by an in vitro assay that measured the ability of glioma cell sonicates to remove a 
methyl group adduct from the 0 6-position of guanine in a 32P-labelled 18 bp DNA 
substrate, are the mean ..±. S.D. of three independent experiments expressed as 
percent of '1'98 MGMT activity. 
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glioma cell sonicates is thus proportional to the relative levels of repaired 18 bp 
DNA substrate following incubation of the 06-methylated 18 bp DNA with glioma cell 
sonicates. After incubation, the methyl-adducted and repaired 18 bp DNA were 
distinguished by digestion with Pvull. (Pvull is sensitive to methyl adducts at 0 6-
guanine and therefore does not cut the adducted 18 bp DNA). The products of 
Pvull digestion of the repaired 18 bp DNA were radiolabelled 8 bp and unlabelled 
10 bp DNA. The 8 bp and 10 bp DNA were size separated from the adducted (and 
therefore uncleaved) 18 bp DNA by electrophoresis through a 20 % denaturing 
polyacrylamide gel. The gel was autoradiographed directly to detect the 
radiolabelled 8 nt and 18 nt DNA. The relative proportion of 8 bp to 18 bp DNA 
following incubation of the 0 6-methylguanine-containing 18 bp DNA with glioma 
cell sonicates is thus directly related to the amount of MGMT activity within the 
cell sonicate. 
Figure 6 shows an MGMT assay of glioma cell sonicates. There was no 
detectable cleavage of the unreacted probe with (P) or without (C) Pvull digestion, 
indicating that prior to incubation with glioma cell extracts the probe was fully 
methylated at the 0 6-position of guanine. Substantial (70-90%) digestion of the 
probe to a 12 bp fragment by Haelll (H) indicated that the probe DNA was not 
inherently resistant to RE digestion. MGMT activity increased in a linear fashion 
with increasing amounts of protein added. Quantitation of MGMT activity in each 
cell line, expressed as a mean+/- standard deviation from three independent assay 
samples, is shown in table 2. The rank order of the MGMT expressing glioma cell 
58 
lines according to MGMT activity, from highest to lowest, was SF763, SF767, T98, 
U138, NAT, HS683, and U373. MGMT activity is undetectable, in this assay system, 
in glioma cell lines A1235, CLA and CRO, consistent with the lack of detectable 
MGMT mRNA in these cell lines. Differences in the rank order of cell lines 
according to MGMT mRNA versus MGMT activity may reflect small differences in 
post-transcriptional events such as mRNA stability, translation efficiency or protein 
half-life. 
Analysis of MGMT Gene Arraneement 
The absence of MGMT expression in CLA, CRO, and A1235 could result from 
a deletion or rearrangement of the MGMT gene as gliomas frequently lose one copy 
of chromosome 10 (Collins and James, 1993) and/or have deletions of lOq 
(Karlbom, et al., 1993), the location of the MGMT gene (Natarajan, et al., 1992). 
The structure of the MGMT gene was therefore assessed in each glioma cell line 
by Southern blot analysis. Figure 7 A and 78 represent Southern blots of Mspl and 
EcoRI digested DNA, respectively, hybridized with a radiolabelled MGMT cDNA. 
The identity of hybridization patterns across all cell lines in each blot (except SF763 
in the Msp blot) indicates that the lack of MGMT expression in the 3 MGMT- cell 
lines was not a result of deletion or gross rearrangement of the MGMT gene. The 
additional MGMT cDNA-recognized Msp fragment in the MGMT+ cell line SF763 
is likely unrelated to (or not required for) MGMT expression as it is not detected 
in any of the other MGMT+ cell lines. The lack of MGMT mRNA and MGMT 
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Figure 7. Southern blot analysis of MGMT gene structure in glioma cells. Ten µg 
of DNA from each glioma cell line was digested with Mspl (10 U / µg DNA) or EcoRI 
(10 U / µg DNA). The DNA was extracted, precipitated and resuspended in ddH20 
and loading dye. The DNA was electrophoresed through a 1% agarose gel, 
transferred to a nylon membrane and hybridized to a 730 hp radiolabelled MGMT 
cDNA probe. The membranes were washed under stringent conditions (as des.cribed 
in fig.5), dried and autoradiographed for 2 - 4 days in the presence of intensifying 
screens. 
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activity, despite the presence of an intact MGMT gene suggests that the MGMT 
gene is regulated at the transcriptional level. The possibility that point mutations 
or very small deletions inactivate the MGMT gene cannot be excluded, but is 
considered unlikely, as the low frequency of point mutations in genes is incongruous 
with the high incidence of MGMT- cell lines (20 - 30%). Recent studies have 
suggested that other mechanisms of gene inactivation, such as changes in cytosine 
methylation, which occur frequently in tumor cells (Goelz and Vogelstein, 19S5; De 
Bustros, et al., 19SS), may influence MGMT gene expression (Pieper, et al., 1991). 
Quantitative Analysis of MGMT Gene Methylation in Glioma Cell Lines 
In order to examine the relationship between methylation and MGMT 
expression in a quantitative fashion, the percent of MGMT gene alleles that were 
methylated at an MGMT intron I site, 5kb upstream of the translation start site (* 
in fig. 3), within each glioma cell line was determined by Southern blot analysis with 
EcoRI digested glioma DNA (fig. SA) and then compared to MGMT mRNA levels 
by linear regression analysis (fig.SB). As a result of the methylation sensitivity of 
EcoRI (EcoRI will not cleave at its recognition site, GAATTC, if the cytosine is 
followed by a guanine and the cytosine of this CG dinucleotide is 
methylated)(Nelson, .fil.Jtl., 19S9), when the 3' EcoRI site flanking the 3.S kb EcoRI 
intron 1 segment of the MGMT gene (see tig.3) was methylated in glioma DNA, the 
DNA was cut at the next available EcoRI site, approximately 0.7 kb downstream, 
generating a larger, 4.5 kb fragment. The proportion of 4.5 kb to 4.5 kb + 3.S kb 
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fragments in the DNA of each cell line was therefore a measure of the percent of 
methylated (at this site) MGMT gene alleles within a population of glioma cells. 
In figure SA, the cell lines are arranged from left to right in order of decreasing 
MGMT expression. The results of this analysis demonstrate that methylation was 
graded across the cell lines at the intron 1 EcoRI site and increased with increasing 
MGMT expression (fig.S). The methylation status of this intron 1 site correlates 
(r= O.S57, p < .001, fig.SB) with MGMT mRNA levels in a similar, positive fashion 
as previously seen in MGMT exons (Pieper, et al., 1991). The two minimally 
MGMT+ cell lines had methylation levels similar to those in MGMT- cell lines. 
The percent methylation at this site within each cell line varied on average less than 
20 percent between two experiments (which were done four months apart) 
indicating that the partial methylation status of this site within each cell line may 
be stable over time. 
Analysis of the Methylation Status of Introns of the MGMT Gene 
To determine if the graded relationship between methylation and MGMT 
expression noted at the intron 1 site (and previously in exons) is present in a 
uniform fashion across the body of the MGMT gene, the methylation status of 
intron regions, 4-10 kb distant from the nearest exons and >25 kb distant from 
each other, across the body of the gene was examined in the glioma cells lines. 
Southern blots ofMspl (methylation insensitive) and Hpall (methylation sensitive) 
digested glioma DNA were hybridized separately with 3 intron probes. The probes 
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Figure 9. Southern blot analysis ofMspl/Hpall site (CCGG) methylation in MGMT 
intron 1. DNA from MGMT expressing (MGMT+) and nonexpressing (MGMT-) 
glioma cell lines was digested with either A) Mspl (7-10 U/µg DNA) or B) Hpall 
(7-10 U/µg DNA), followed by digestion with EcoRI (10 U/µg DNA). Following 
electrophoresis through a 1.0% agarose gel and transfer to a nylon membrane the 
DNA (10 µg/sample), arranged from left to right in order of decreasing MGMT 
expression in the cell line of origin, was hybridized with a 32P-labelled 3.8 kb 
MGMT intron 1 fragment derived from genomic clone ld and located 5 kb 5' of 
exon 2 (see fig.3). Hybridized membranes were washed under stringent conditions 
(as described in fig.5) and then autoradiographed (4 days) in the presence of 
intensifying screens. 
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were derived from 5', middle, and 3' intron regions of the MGMT gene. The 
locations of each intron segment within the MGMT gene are depicted in fig. 3. 
Southern blot analysis of the methylation status of a 3.8 kb MGMT intron 1 
region, located approximately 5 kb 5' of exon 1 and 45 kb 3' of the MGMT 
promoter (see fig.3, intron probes), in the glioma cell lines is shown in figure 9. The 
pattern of intron 1 probe-hybridization to Mspl digested DNA from the glioma cell 
lines (fig.9A) was the same in all lanes (with the exception the MGMT gene in CRO, 
lane 7, which has a point mutation or very small deletion in all alleles)), indicating 
that the 3.8 kb intron 1 region was identical, with respect to the number and 
location of Mspl/Hpall sites. Southern blot analysis of Hpall digested DNA from 
glioma cell lines (fig.9B), arranged from left to right in order of decreasing MGMT 
expression, indicates that the intron 1 segment of the MGMT gene was relatively 
unmethylated (lower molecular weight, greater degree of Hpall digestion) in the 
minimally MGMT+ and MGMT- cell lines and methylated (higher molecular 
weight, less Hpall digestion) in the MGMT+ cell lines, consistent with the 
quantitative analysis of methylation of the EcoRI CpG bordering this region. 
Additionally, the similarity in percent methylation of the intron 1 EcoRI site in 
HS683 and U373 (both minimally MGMT+ cell lines) compared to MGMT- cell 
lines was also detected in the extent of Hpall site methylation in intron 1 (fig.9B). 
The presence of both the methylated and unmethylated fragments in Hpall digested 
DNA from the MGMT+ glioma cell lines (fig. 9B, lanes 1-4) suggests the existence 
of allelic differences (within a single cell) and/or population differences (within 
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Figure 10. Analysis of the extent of Mspl and Hpall digestion of the samples 
described in fig.9. Aliquots (20 µl) of each digestion reaction were removed from 
the primary digests (Mspl and Hpall digests, fig.9) and incubated with a uniformly 
32P-labelled MGMT cDNA. The samples were electrophoresed through a 1.5 % 
agarose gel, transferred to a nylon membrane and autoradiographed (1 - 4-hr) in 
the presence of intensifying screens. 
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Figure 11. Southern blot analysis of Mspl/Hpall site methylation in MGMT intron 
3. A) Mspl and B) Hpall digested DNA from each glioma cell line was analyzed 
by Southern blot analysis as described in fig.9 except that hybridization was with 
a 32P-labelled MGMT intron 3 fragment derived from genomic clone 7c and located 
10 kb 3' of exon III (see fig.3). Complete digestion of all samples was determined 
as described in fig.10. 
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each cell line) in MGMT gene methylation patterns. The variable hybridization 
intensities within each lane and across lanes likely reflect the degree of 
heterogeneity in methylation at various MGMT intron sites, i.e., a greater degree of 
heterogeneity in MGMT gene methylation within a cell line results in fewer copies 
of a given Hpall fragment and thus weaker hybridization signal for that fragment. 
To exclude the possibility that the differences in the extent of Hpall digestion of the 
MGMT gene from each glioma cell line might be due to incomplete Hpall digestion, 
rather than methylation differences, control digests were performed. Incubation of 
20 µl of each primary Hpall digest (as well as Mspl digests) with a uniformly 32P-
labelled MGMT cDNA, followed by electrophoresis and autoradiography, resulted 
in an identical digestion pattern in all the samples (fig.10). This suggests that the 
digestion was complete in the primary Hpall and Mspl digests, and the differences 
in extent of digestion in the primary samples can be attributed to methylation. 
Control digests were performed for each independent experiment. 
Southern blot analysis of the methylation status of a 3.8 kb intron 3 region, 
10 kb 3' of exon 3 (see fig.3, intron probes) is shown in figure 11. Analysis of Mspl 
digested glioma DNA indicated that the number and position of Mspl/Hpall sites 
in this intron 3 region was the same in all cell lines, regardless of MGMT 
expression (fig.HA). Figure 118 demonstrates that Hpall sites throughout this 
intron 3 region (6 kb through 14 kb 3' of exon 3) were methylated in MGMT+ 
glioma cell lines and relatively unmethylated in minimally MGMT+ and MGMT-
glioma cell lines. The presence of a 1.1 kb fragment in all lanes (fig.118) indicates 
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Figure 12. Southern blot analysis of Mspl/Hpall site methylation in the 3' end of 
the MGMT gene. A) Mspl and B) Hpall digested DNA samples from each glioma 
cell line were analyzed by Southern blot analysis as described in fig.9 except 
hybridization was with a 32P-labelled 3.5 kb Eagl fragment derived from genomic 
clone llb and located 4 kb 3' of exon 5. Complete digestion of all samples was 
determined as described in fig. 10. 
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Figure 13. Southern blot analysis of Mspl/Hpall site methylation in normal human 
T lymphocytes (T cells) and brain, and in a brain tumor sample (GBM). Mspl 
(lanes 1 - 4) and Hpall (lanes S - 8) digested DNA from the human normal and 
tumor cells was analyzed by Southern blot analysis as described in fig.9 (including 
use of the same intron 1 probe). 
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that the two Hpall sites flanking this fragment were unmethylated to an extent, 
estimated by hybridization intensity, in all cell lines, with the greater number of 
unmethylated alleles in the MGMT- cell lines (fig. llB). The strong hybridization 
to high molecular weight Hpall fragments from MGMT+ cell lines (fig.11, lanes 1-
4) indicates that in a large number of these cells all Hpall sites were methylated 
over 7-12 kb of intron 3. 
Analysis of methylation in the 3' end of the MGMT gene, shown in fig.12 
yielded results similar to those in intron 1, intron 3 and exons, i.e. the MGMT gene 
was methylated in MGMT+ cell lines and relatively unmethylated in minimally 
MGMT+ and MGMT- cell lines. These results suggest that, within each cell line, 
the methylation status of the MGMT gene is uniform over > 80 kb defined by the 
probes used and correlates in a positive, graded fashion with MGMT expression. 
The body of the MGMT gene was also heavily methylated in several 
noncultured human cells that express the MGMT gene. Figure 13 shows a Southern 
blot analysis of Mspl/EcoRI (lanes 1-4) and Hpall/EcoRI (lanes 5-8) cut DNA 
from a normal human brain sample, a glioblastoma multiforme tumor sample 
(GBM), and T lymphocytes, hybridized with the MGMT intron 1 probe. The 
number and position of Mspl sites in this region was the same in T cells and 
normal brain, but an additional band of 2.4 kb was present only in the tumor 
sample. The 2.4 kb band corresponds exactly to the Mspl fragment seen in the 
intron I from CLA cells (fig.9A) and may therefore be derived from a point 
mutation, common to CLA cells and > 50 % of the cells in the tumor sample, that 
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destroys an Mspl site flanking the 2.0 kb Msp I fragment. The MGMT gene was 
methylated at virtually all the Hpall sites in intron 1 of T lymphocytes, which have 
relatively high levels of MGMT activity (approximately 3-4 times the level in the 
T98 cell line). The MGMT gene in the tumor and normal human brain samples 
was also methylated to a level similar to the MGMT+ glioma cell lines, which 
express similar levels of MGMT, but to a lesser extent than in T lymphocytes. The 
somewhat decreased level of methylation in the brain sample compared to the tumor 
was consistent with the slightly lower level of MGMT activity in the brain sample. 
The apparent heterogeneity of MGMT methylation in the normal brain sample 
might be explained by differences in MGMT gene methylation patterns in the 
different cell types present in this sample. 
RE Accessibility to the Body of the MGMT Gene within Intact Nuclei 
The observation that methylation of the body of the MGMT gene correlated 
in a direct, graded fashion with MGMT expression suggested that there may be 
methylation related differences in chromatin structure of the body of the gene. The 
chromatin structure of the body of the MGMT gene was examined by determining 
the relative accessibility of Mspl, Alul, and DNasel to the body of the MGMT gene 
within isolated nuclei from MGMT+ and MGMT- glioma cells. Since both histones 
and methylated DNA binding proteins (MeCps) block RE digestion in nuclei (Tazi 
and Bird, 1990; Antequera, et al., 1989) ), this analysis assesses, at least, the 
combined effect of these proteins on chromatin structure. 
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Figure 14. Southern blot analysis of Mspl accessibility to and methylation of an 
MGMT intron 1 region. For analysis of Mspl accessibility to the MGMT gene, 
nuclei from MGMT+ (SF767) and MGMT- (CLA) glioma cells were incubated with 
Mspl (lanes 1,6; 20 U Mspl for 10 min, lanes 2,7; 150 U Mspl for 2 hr), the DNA 
was isolated and further cleaved with EcoRI. For analysis of intron 1 methylation, 
DNA was also isolated from untreated nuclei and digested with Mspl/EcoRI (lanes 
3,8), Hpall/EcoRI (lanes 4,9) or EcoRI only (lanes 5,10). The DNA from all the 
samples was analyzed by Southern blot as described in fig.9 (including use of the 
same intron 1 probe). 
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Figure 15. Southern blot analysis of Mspl accessibility to and methylation of an 
MGMT intron 1 region in MGMT+ (1'98) and MGMT- (A1235) glioma cells. 
Analysis ofMspl accessibility to the MGMT intron 1 region within intact nuclei and 
methylation analysis of naked DNA were performed exactly as described in fig.14. 
Lanes 1,6; nuclei incubated with 20 U Mspl for 10 min, lanes 2,7; nuclei incubated 
with 150 U Mspl for 2 hr, lanes 3,8; Mspl/EcoRI cut naked DNA, lanes 4,9; 
Hpall/EcoRI cut naked DNA, lanes 5,10; EcoRI cut naked DNA. 
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Figure 16. Southern blot analysis of Mspl accessibility to and methylation of an 
MGMT intron 1 region in MGMT+ (T98) and MGMT- (Colo) cells. Analysis of 
Mspl accessibility to the MGMT intron 1 region within intact nuclei and 
methylation analysis of naked DNA were performed exactly as described in fig.14. 
Lanes 1,6; nuclei incubated with 20 U Mspl for 10 min, lanes 2,7; nuclei incubated 
with 150 U Mspl for 2 hr, lanes 3,8; Mspl/EcoRI cut naked DNA, lanes 4,9; 
Hpall/EcoRI cut naked DNA, lanes 5,10; EcoRI cut naked DNA. 
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The recognition site for Mspl (CCGG) contains a CpG and Mspl 
accessibility to DNA in nuclei may therefore be directly influenced by MeCps 
(Antequera, et al., 1989). Comparison of the relative accessibility of Mspl to 
MGMT gene sequences within nuclei as well as confirmation of the methylation 
status of the MGMT gene was accomplished by Southern blot analysis using the 3.8 
kb Eco RI intron 1 probe described above. As a result of the methylation sensitivity 
of EcoRI, the 3.8 kb intron 1 probe recognized two fragments in the EcoRI only 
digests of naked DNA (fig.14-16 lanes 5, each panel). The larger, 4.5 kb fragment 
was generated from MGMT alleles methylated at the EcoRI site that defines the 3' 
end of this probe. The MGMT expressing cell lines had a greater proportion of the 
4.5 kb fragments (fig.14-16, lanes 5) indicating a greater degree of methylation at 
this site in MGMT+ cells compared to MGMT- cells (lanes 10). Consistent with 
the EcoRI digests, the EcoRI/Hpall (fig. 14-16, lanes 4,9) digests also confirm that 
the intron 1 region was methylated in the MGMT+ cell lines and relatively 
unmethylated in the MGMT- cell lines. There was no difference in digestion 
patterns when the glioma DNA was incubated with the methylation insensitive 
enzyme, Mspl (fig.14-16, lanes 3,7). Comparison of the Msp digests of DNA in 
nuclei demonstrates that the unmethylated MGMT gene-intron 1 region in MGMT-
cells is more accessible to Mspl relative to the methylated intron 1 in MGMT 
expressing cells, indicated by the presence of three additional probe-recognized 
fragments in the DNA from MGMT- cells (fig. 14-16, ~,lanes 1-2) not seen in the 
digests of DNA from MGMT+ cells (SF767, lanes 6-7). Incubation of the nuclei 
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with 20 U Mspl for 10 min (fig. 14-16, lanes 1,6) yielded the same degree of 
digestion as incubation with 150 U Mspl for 2 hrs (lanes 2,7). The differential Msp 
accessibility in the intron 1 region is consistent across all 5 cell lines tested (fig. 14-
16), suggesting that the methylation-related chromatin structure in the body of the 
gene may be a relevant component of MGMT transcription. Furthermore, the 
positions of the accessible Mspl sites were identical in the nuclei from all three 
unrelated MGMT- cell lines tested, and two minimally MGMT+ cell lines (which 
are also relatively unmethylated) supporting the idea that methylation and 
chromatin structure in the body of the MGMT gene are closely linked, possibly 
through MeCps. 
As opposed to Mspl, enzymes With non-CpG-containing recognition sites are 
only blocked by MeCps if their sites are near a CpG (Antequera, et al., 1989). To 
determine if the differences in chromatin structure can be detected with enzymes 
that do not contain CpGs in their recognition sequence, the accessibility of Alul to 
the MGMT gene within nuclei was tested. Nuclei from 2 MGMT+ and 2 MGMT-
glioma cell lines were incubated with increasing amounts of Alul, the DNA was 
isolated and cleaved with EcoRI and analyzed by Southern blot with the 3.8 kb 
intron 1 probe (fig.17-18). Increasing the amount of Alul in the reaction resulted 
in increased cleavage primarily in the MGMT- nuclei, but also, to a much lesser 
degree in one of the two MGMT+ nuclei (fig.17, SF767). The extent of Alul 
digestion of the MGMT gene was nevertheless significantly greater in MGMT-
nuclei compared to MGMT+ nuclei, especially in nuclei incubated with 60 U Alul 
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Figure 17. Southern blot analysis of Alul accessibility to an MGMT intron 1 region 
within intact nuclei from MGMT+ (SF767) and MGMT- (CLA) glioma cells. 
Nuclei were incubated with Alul (0 - 60 U for 10 min), the DNA was isolated and 
further cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by 
Southern blot with the intron 1 probe as described in fig.9. 
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Figure 18. Southern blot analysis of Alul accessibility to an MGMT intron 1 region 
within intact nuclei from MGMT+ (T98) and MGMT- (A1235) glioma cells. Nuclei 
were incubated with Alul (0 - 60 U for 10 min), the DNA was isolated and further 
cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by Southern blot 
with the MGMT intron 1 probe as described in fig.9. 
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Figure 19. Southern blot analysis of DNasel accessibility to an MGMT intron 1 
region within intact nuclei from MGMT+ (SF767) and MGMT- (CLA) glioma cells. 
Nuclei were incubated with DNasel (0 - 60 U for 10 min), the DNA was isolated and 
further cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by 
Southern blot with the intron 1 probe as described in fig.9. 
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Figure 20. Southern blot analysis of DNasel accessibility to an MGMT intron 1 
region within intact nuclei from MGMT+ (T98) and MGMT- (A1235) glioma cells. 
Nuclei were incubated with DNasel (0 - 60 U for 10 min), the DNA was isolated and 
further cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by 
Southern blot with the intron 1 probe as described in fig.9. 
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(flg.17,18, compare lanes 4 and 8). Thus, the different chromatin structures of the 
MGMT gene within MGMT- and MGMT+ nuclei can be distinguished at CpG-
containing and nonCpG-containing sites. 
The chromatin structure of the body of the MGMT gene was also analysed 
with a non-sequence specific enzyme, DNAsel, which cleaves DNA in the minor 
groove (reviewed in Gross and Garrard, 1988). DNAseI cleaves at nucleosome free 
regions (often synonymous with DNAseI hypersensitive sites) when added at low 
concentrations to nuclei, and at internucleosomal and intranucleosomal DNA at 
much higher concentrations. Nuclei from two MGMT+ and two MGMT- glioma 
cell lines were incubated with increasing amounts of DNAseI, after which DNA was 
isolated, cleaved with EcoRI and analyzed by Southern blot with the MGMT intron 
1 probe (fig.19, 20). DNaseI did not cleave intron 1 at any of the concentrations 
shown in these experiments (fig.19,20). The average sized DNA fragment from these 
digests, as determined by visual inspection of the agarose gels prior to transfer, 
decreased with increasing DNaseI, indicating that much of the genome was cleaved 
by DNase, yet the body of the MGMT gene was very resistant to cleavage. 
Incubation of the nuclei with 120 U DNase resulted in complete loss of hybridizable 
DNA fragments in each cell line. Thus, there were no detectable differences in the 
presence or absence of nucleosomes in the body of the MGMT gene in nuclei from 
MGMT+ and MGMT- glioma cell lines. 
In summary, MspI and AluI accessibility to the body of the MGMT gene was 
greater in nuclei from MGMT- cells relative to MGMT+ cells but MspI 
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accessibility was independent of Mspl concentration whereas Alul accessibility 
increased with increasing Aloi added. The greater Mspl and Aloi accessibility in 
MGMT- nuclei was likely not a result of the absence of nucleosomes in these cells 
since no differences in DNasel digestion were seen at any of the DNasel amounts 
tested, but may involve MeCps. Binding of MeCps to the methylated MGMT gene 
could be relevant in mediating the relationship between methylation and MGMT 
expression by maintaining the chromatin structure of the MGMT gene in a manner 
that facilitates transcription. These data suggest that alterations in methylation 
and chromatin structure in the body of the MGMT gene may be a common feature 
associated with loss of MGMT gene expression. 
Analysis of Methylation in the MGMT Promoter 
The methylation status of the MGMT promoter was determined by linker-
mediated PCR (LMPCR) analysis of hydrazine treated glioma DNA. As hydrazine, 
in the presence of 1.5 M NaCl, reacts preferentially with cytosine but not 5-
methylcytosine (Ohmori, et al., 1978), methylated cytosines decrease the intensity, 
or cause the disappearance of cytosine bands in sequenced DNA. Methylation was 
analyzed in two regions of the MGMT promoter that together likely contain all the 
basal promoter elements and approximately 60 percent of full promoter activity 
(Harris, et al., 1991). Region I includes nucleotides 703-800 and region II, which 
includes the transcription start site (nt 955), spans the basal promoter elements 
(nucleotides 865-1020) (Harris, et al., 1991). The full nucleotide sequence of these 
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Figure 21. Methylation analysis of the MGMT promoter in MGMT+ (SF767), 
minimally MGMT+ (Hs683) and MGMT- (CLA) glioma cells by LMPCR. DNA 
from the glioma cell lines and plasmid DNA containing a 1.2 kb BamH I/Sst I 
fragment of the MGMT promoter was reacted with genomic sequencing chemicals. 
All nucleotides (G, guanine, A, adenine, T, thymine, C, cytosine) in the cloned DNA 
and guanines and cytosines in the glioma DNA spanning promoter nt 703-800 (A, 
region I) and 865-1020 (B, region II) were analyzed by LMPCR. A MGMT 
promoter-specific primer (region I, nt 655-675 and region II, nt 805-823), was 
annealed to the cleaved DNA and extended (48°C, 15 min) with Sequenase. 
Extension products were ligated to a double stranded linker and then amplified by 
PCR (5 min, 95°C followed by 18 cycles of 95°C for 1 min, 66°C for 2 min and 76°C 
for 3 min with a 5 sec extension of the 76°C step after each cycle and 10 min at 
76°C after cycle 18) with the longer (25 mer) linker primer and a nested gene-
specific primer (for promoter region 1, nt 674-698, for promoter region 2, nt 841-
861). 32P labelled PCR products were generated through two additional PCR cycles 
with a second nested end-labelled primer (for promoter region I, nt 674-702, for 
promoter region 2, nt 841-864). Following two cycles of PCR (same parameters as 
above except annealing was at 67°C and extension at 77°C), the DNA was extracted, 
precipitated, and resuspended in 10 µI. 3 - 5 µl of the sample was electrophoresed 
through a 6 % denaturing polyacrylamide gel and then detected by autoradiography 
(6-18 h exposure). (•)indicate cytosines within a CpG. 
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regions in the cloned promoter as well as the positions of guanines in the glioma 
DNA were also confirmed using genomic sequencing chemicals and LMPCR. 
Figure 21A and 21B represent autoradiographs of the promoter methylation 
analysis in region I and region II, respectively. In both promoter regions, the 
relative intensity of most bands representing potentially methylated cytosines 
(numbered arrows) decreases, indicating fewer unmethylated cytosines, from SF767 
(MGMT+) to Hs683 (minimally MGMT+) and CLA (MGMT-) amplified DNA. 
Methylation in these MGMT promoter regions appears uniform within each cell line 
and correlates in an inverse, rather than direct, fashion with MGMT expression. 
The radioactive signal from 25 of the cytosine bands (of a CpG) was 
quantitated directly from the polyacrylamide gels and compared to a nearby non 
CpG cytosine to obtain a relative ratio (CpG cytosine/non-CpG cytosine) that 
reflects the level of methylation at that site. Determining relative values in this 
manner eliminates value variations potentially due to unequal ligation, 
amplification, or sample loading. The relative ratios from glioma cell DNAs were 
compared to plasmid DNA containing the MGMT promoter (100 percent 
unmethylated at all sites)(region I, fig.22A) or to the SF767 cell line DNA (region 
II, fig.22B). The results are expressed as percent of MGMT promoter alleles within 
each cell line that were unmethylated at a particular site, as the signal measured 
was a result of unmethylated cytosines. Methylation appears uniform within each 
cell line and graded across the cell lines at eight of ten sites (exceptions are sites 
3 and 6) in region I and thirteen of fifteen sites (exceptions are sites 11 and 13) in 
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Figure 22. Quantitation of promoter methylation in MGMT+ (SF767), minimal],~ 
MGMT+ (Hs683) and MGMT- (CLA) glioma cell lines. Promoter methylation w~~ 
quantitated by measuring radioactive signal from the LMPCR products i~ 
polyacrylamide gels using a betascope 603 blot analyzer. Methylation values of eac~ 
CpG were calculated as the ratio of unmethylated cytosine (in a CpG) to ~ 
neighboring non-CpG cytosine. A, For promoter region I (nt 703-800), methylatio~ 
from each cell line was expressed relative to the MGMT promoter in plasmid DN~ 
(100 % unmethylated), and was the average of two independent experimen \ 
(average difference of 8.6 % between experiments). B, Methylation of CpG's ·~ 
region II (nt 865-1020) was expressed relative to the SF767 cell line. 
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region II, and correlates in an inverse, rather than direct fashion with MGMT 
expression. Of the four apparently non-graded sites, three (sites 3,6,11) are still 
methylated to a greater extent in the nonexpressing cell lines compared to 
expressing cell lines, and one (site 13) is unmethylated in all cell lines. The graded 
methylation patterns at the majority of sites across the cell lines implies that there 
is a close, inverse relationship between methylation of the promoter and MGMT 
expression. 
Restriction Enzyme Accessibility to the MGMT Promoter within Nuclei 
Because the methylation status of the MGMT promoter was associated with 
MGMT expression in a graded, inverse fashion, the possibility that methylation may 
influence the chromatin structure of the MGMT promoter, and thus MGMT 
transcription, was investigated. The chromatin structure of the MGMT promoter 
was analyzed by incubation of nuclei from MGMT expressing and nonexpressing 
cells with AvaII or Mspl followed by LMPCR analysis of the DNA. 
Figure 23A and 23B show the results of LMPCR analysis of the AvaII 
accessibility to promoter region I and region II, respectively. The LMPCR products 
of 127 nt (fig.23A) and 140 nt (flg.23B) correspond exactly to the distance between 
the labelled LMPCR primers and the Avail sites at nucleotides 773 and 953 of the 
MGMT promoter, respectively. The large amount of LMPCR product generated 
from DNA of the SF767 nuclei digests and virtual absence from equal amounts of 
Hs683 and CLA DNA indicates that the MGMT promoter is much more accessible 
91 
l:'- ' C") l:'- C") 
co co co CO. 
l:'- co eel l:'- co (1j r:... rn 
-
r:... rn ....... 
r/) ::r: u r/) ::i:: u 
A B 
nt 
-152 -
-140 -
-146 -
-141-
-137-
.. -127-
-120-
-116 -
Figure 23. LMPCR analysis of Avail accessibility to the MGMT promoter within 
intact nuclei. Nuclei isolated from MGMT+ (SF767), minimally MGMT+ (Hs683) 
and MGMT- (CLA) glioma cells were incubated with 16 U Avail for 10 min at 37°C. 
DNA was isolated from the nuclei and 5 µg was analyzed by LMPCR as described 
in fig. 21, except only one-fifth of the final reaction was analyzed, and 
autoradiograph exposures were 2-5 h with intensifying screens. The LMPCR 
products of 127 nt (arrow in A, promoter region I) and 140 nt (arrow in B, 
promoter region II) are derived from glioma DNA cut at the Avail site at promoter 
nt 776 and nt 956, respectively. 
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at both Avall sites, and possibly in a more open chromatin conformation, in nuclei 
from MGMT+ cells (SF767) relative to minimally MGMT+ (Hs683) and MGMT-
cells (CLA). The difference in Avall accessibility between the three cell lines was 
reproducible in independent experiments. It is interesting to note that the 
differentially accessible Avall site at nucleotide 953 falls in the immediate vicinity 
of the transcription start site (955) and several potential Spl binding sites 
(Harris,et al., 1991), where chromatin structure might directly influence MGMT 
transcription. 
Figure 24 represents the LMPCR analysis of MspI accessibility to the MGMT 
promoter in nuclei from MGMT+ (SF767), minimally MGMT+ (Hs683) and 
MGMT- (CLA) glioma cell lines. Incubation of the nuclei with 20 U MspI (lanes 
1- 3) resulted in a much greater cleavage at all promoter MspI sites tested in SF767 
nuclei compared to Hs683 and CLA. The difference in MspI accessibility was also 
reproducible in independent experiments. Together, all the MspI and Avall sites 
are accessible in nuclei from SF767 cells and encompass 372 nt (nt 712-1084, 
including an additional MspI site (nt 884) and an Avail site (nt 1084)), a region 
of accessible DNA much larger than would be expected if normal nucleosomal 
phasing was present (McGhee, et al., 1980). Incubation of nuclei (from the same 
isolation) with an excess of MspI (lanes 4-9) resulted in measurable cleavage at all 
sites, indicating that the absence of LMPCR products is likely not a result of 
contaminants from the nuclei isolation that inhibit MspI digestion or contaminants 
that inhibit enzymes used in LMPCR. The MspI sites at 712, 722 and 738 ·(lanes 
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Figure 24. LMPCR analysis of Mspl accessibility to the MGMT promoter within 
intact nuclei. Nuclei from MGMT+ cells (SF767), minimally MGMT+ cells 
(Hs683) and MGMT- cells (CLA) were incubated with either 20 U (lanes 1-3), 200 
U (lanes 4-6) or 400 U (lanes 7-9) Mspl, the DNA was isolated and 5 µg was 
analyzed by LMPCR. One fifth of each reaction was separated on a 6 % denaturing 
polyacrylamide gel and autoradiographed for 2-5 hr in the presence of intensifying 
screens. 
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1-3) appear to have graded degrees of accessibility across the cell lines that parallel, 
in an inverse fashion, the graded promoter methylation, suggesting that methylation 
and chromatin structure are closely linked in the MGMT promoter. The restriction 
enzyme inaccessible promoter in cells with little or no MGMT expression may also 
be inaccessible to endogenous transcription factors. The chromatin structure of the 
promoter may therefore determine, in part, the expression state of the MGMT gene. 
In Vivo Footprintin& of the MGMT Promoter 
Specific in vivo protein-DNA interactions in the MGMT promoter were 
examined by linker-mediated PCR of DNA from glioma cells that were exposed to 
dimethylsulfate (DMS). As DMS reacts preferentially with the N7 position of 
guanines, and subsequent piperidine treatment of the isolated DNA results in 
cleavage of the DNA at DMS-methylated guanines (Mattes, et al., 1986), the 
LMPCR products generated from this DNA represent the guanines that are 
accessible to DMS within intact cells. As DMS is not blocked by nucleosomes or 
MeCPs but DNA is protected from DMS by many transcription factors (Pfeifer, et 
al., 1989a), the DMS footprinted protein-DNA interactions are qualitatively different 
from those assessed by Mspl accessibility. 
Figure 25 shows the in vivo footprint analysis of the MGMT promoter, in 
MGMT expressing and nonexpressing cells, from nucleotides 700-865 (fig.25A) and 
865-1050 (fig.25B), which together include the transcription start site (nt 955) and 
likely all the basal promoter elements. There are no detectable footprints in any of 
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Figure 25. In vivo footprint analysis of DNA-protein interactions in the MGMT 
promoter. Normal human T lymphocytes (lane 1) and two glioma cell lines all with 
high levels of MGMT expression (lanes 2-3), one minimally MGMT+ glioma cell 
line (lane 4), and three MGMT- glioma cell lines (lanes 5-7) were incubated with 
0.1 % DMS (2 min, 37°C). DNA was isolated from the cells, cleaved with piperidine, 
and 5 µg analyzed by LMPCR. One half of the reaction was separated on a 6 % 
denaturing polyacrylamide gel and autoradiographed for 6-18 hrs. A, Analysis of 
promoter nt 700-865; B, analysis of promoter nt 865-1050. Open rectangles are Spl 
sites unoccupied in all cells tested. Filled rectangle (I) indicates site that is 
footprinted in lanes 1-3 but not in lanes 4-7. Except for the footprint at nt 845-855 
(in A, nt sequence given vertically), which is an as yet uncharacterized site, all 
footprinted regions are Spl consensus sequences (GGGCGG). -+ in B indicates 
transcription start site. 
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the cells in the region spanning nucleotide 700-845 (fig.25A), which includes a 
putative Spl recognition site (nt 708-713). The guanines at positions 849,851, and 
852 however, are protected from DMS in the MGMT+ cells (lanes 1-3) but not in 
the minimally MGMT+ (lane 4) and MGMT- cells (lanes 5-7), indicating the 
presence of an MGMT expression-associated DNA-protein interaction. The 
protected sequence does not match with any known consensus sequence for 
transcription factor binding and may thus represent a novel protein binding site. 
In the promoter region spanning nt 865-1050 there are 6 footprints in the MGMT+ 
cells but none in the minimally MGMT+ or MGMT- cells. All six of these 
footprints correspond to Spl recognition sequences and have 5' hypersensitive 
guanines followed by at least five protected guanines, indicating that in MGMT+ 
cells, these sequences are likely protected by Spl. There are no footprints at the two 
overlapping Spl-like sequences spanning nt 875-885, or at the putative CCAAT box 
(nt 870-876) in any of the cells tested (fig.258). Normal human T cells, which have 
high levels of MGMT expression, have an identical pattern of footprints as the 
MGMT+ glioma cell lines, indicating that these DNA-protein interactions are not 
confined to cell lines. Spl appears to be a common feature of and possibly critical 
for efficient basal level MGMT transcription. These data strongly suggest that the 
chromatin structure of the MGMT promoter determines whether Spl and other 
transcription factors can interact with the promoter in vivo, and likely influences 
the expression state of the MGMT gene. 
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Figure 26. Gel mobility shift analysis of basal Spl binding activity. Ten µg of 
protein extract from each cell line were incubated with a double-stranded, . 32P-
labeled oligonucleotide containing Spl consensus sequences. The protein-bound and 
unbound (free) oligonucleotides were separated by electrophoresis through a 4% 
non-denaturing polyacrylamide gel and then detected by autoradiography. Lane 1: 
no protein, lane 2; 10 µg HeLa protein extract, lane 3; Hela extract preincubated 
with excess cold Spl oligonucleotide (specific competitor), lane 4; HeLa extract 
preincubated with excess cold HSE oligonucleotide (nonspecific competitor), lane 
5-14; 10 µg protein extract from various cell lines, as noted. 
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Analysis of Spl Hindin& Activity 
To ensure that the absence of Spl footprints in MGMT- was not simply due 
to a lack of Spl protein in these cells, Spl binding activity was measured in protein 
extracts from all the glioma cell lines by gel shift analysis. Ten µg of protein 
extract from each glioma cell line was incubated with a radiolabelled 22 bp DNA 
probe that contains a single Spl binding site. Spl binding activity was detected by 
separating the free probe from Spl-bound probe (migrates much slower) by 
electrophoresis through a 6% nondenaturing polyacrylamide gel and 
autoradiography. 
The results of the Spl gel shift analysis are shown in fig. 26. Probe alone (no 
protein extract) migrates near the bottom of the gel (lane 1). Three control 
reactions were performed to demonstrate that the protein bound to the Spl probe 
is in fact Spl. Incubation of the probe with HeLa cell extract (positive control for 
Spl) resulted in a slower migration of the probe through the gel because it is bound 
by Spl (a "gel shift," lane 2). Complete elimination of the HeLa cell Spl gel shift 
by preincubation of the HeLa extract with an excess of unlabelled Spl probe (self 
competition, lane 3) but no such effect by preincubation with an excess with an 
unlabelled 22 hp heat shock DNA (nonself competition, lane 4) indicated that the 
protein responsible for the gel shift was specific for the Spl probe and likely was 
Spl. Gel shifts identical to that seen with HeLa cell extract were easily detectable 
in all the glioma cell lines tested (lanes 4-13). All the glioma cell lines therefore 
have functional Spl protein, regardless of MGMT expression. These data clearly 
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demonstrate that the lack of Spl footprints in vivo in MGMT- cells was not due to 
a lack of Spl in these cells and coupled with the data described above, provides 
compelling evidence for the involvement of methylation and chromatin structure in 
MGMT expression. 
CHAPTERV 
DISCUSSION 
This dissertation was designed to examine the role of cytosine methylation in 
the regulation of MGMT gene expression in human glioma cells. The results of 
these experiments strongly support the hypothesis that methylation and chromatin 
structure are important components of MGMT gene expression in human glioma 
cells. The interpretation, significance, and potential limitations of the results 
leading to this conclusion are discussed below. 
From the outset it should be acknowledged that regulation of MGMT gene 
expression has not been proven to occur at the level of transcription. The protein 
coding portions of the MGMT gene are spread over greater than 80 kb (Costello, 
et al., 1994) and the entire gene spans more than 170 kb (Nakatsu, et al., 1993), yet 
the MGMT mRNA is only 1 kb. The standard explanation for generation of the 
mature 1 kb MGMT mRNA involves transcription of all 170 kb of the MGMT gene, 
followed by or concurrent with accurate removal (splicing) of 99.4% of the primary 
transcript (MGMT hnRNA). In a simplistic sense, the process of generating a 
mature MGMT mRNA seems inefficient, and if the RNA polymerase transcribing 
the MGMT gene proceeds at a rate similar to other eukaryotic RNA polymerases, 
generation of a single MGMT hnRNA or mRNA would take at least 17 minutes. It 
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is expected that multiple MGMT transcripts initiated in this time period would 
increase the number of transcripts generated in a given time period. The high 
stability of the MGMT mRNA (half-life > 12 hr (Kroes and Erickson, 1992)), may 
also counterbalance the presumably slow MGMT transcription and thereby 
maintain higher levels of MGMT expression. Currently, it is unknown whether the 
MGMT gene is transcribed in a fashion similar to most other genes. The only 
evidence suggesting that the MGMT gene transcription may be atypical is based on 
negative data. As opposed to the measurable transcription rate of the majority of 
genes, MGMT transcription has not been detected by either nuclear run-on analysis 
or PCR amplification of reverse transcribed hnRNA (Russell Pieper, personal 
communication; Kroes and Erickson, 1992). It is unclear if these negative results 
reflect extremely slow transcription, immediate processing of hnRNA, technical 
artifacts, or some combination of these phenomena. MGMT transcription, and thus 
transcriptional regulation of MGMT expression, cannot be directly assessed in 
either MGMT+ or MGMT- cells. 
Several experiments described in this dissertation and elsewhere (Ostrowski, 
~., 1991) provide indirect evidence for transcriptional regulation of MGMT 
expression. The absence of MGMT mRNA in three of the glioma cell lines, despite 
the presence of a relatively intact MGMT gene suggests that there is a defect in 
transcription in these cells. Additionally, the similarity in the rank order of glioma 
cell lines according to MGMT mRNA levels and MGMT activity indicates that post-
transcriptional regulatory events play little, if any, role in determining the level of 
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MGMT expression (Costello, et al., 1994). The consistently different methylation 
status of the MGMT gene, in both the body and promoter, in MGMT+ cells relative 
to MGMT- cells is also indirect evidence for transcriptional regulation of MGMT 
expression, since transcriptional regulation of gene expression is thought to be 
influenced by cytosine methylation. Additionally, the transcriptionally inactive 
chromatin and absence of bound transcription factors in the promoter of MGMT-
glioma cells strongly supports the idea that the MGMT gene is not transcribed in 
these cells. Thus, MGMT expression is presumed, but not proven, to be regulated 
at the transcriptional level. 
Recently, studies of MGMT gene regulation were advanced by the isolation and 
characterization of the human MGMT promoter (Harris et al., 1991; Nakatsu, et 
al., 1993). The promoter for the MGMT gene has CpG island characteristics and 
lacks TATA and CAAT boxes, similar to promoters for many housekeeping genes. 
MGMT promoter elements required for basal promoter activity (41% of full activity) 
are located between nucleotides 886 and 1157 of the 1157 bp promoter, and contain 
the transcription start site (nt 955) and six putative Spl recognition sites (Harris, 
et al., 1991). In human tumor cells transfected with chloramphenicol 
acetyltransferase (CAT) constructs containing the MGMT promoter, both MGMT 
expressing and nonexpressing cell lines contained the factors necessary for 
transcription initiation from the MGMT promoter (Harris, .rt.J!!., 1992), implying 
that differences between the transfected and endogenous MGMT promoters such as 
methylation status and/or chromatin structure may be important. Changes .in the 
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body of the gene may also however, be relevant in MGMT expression as several 
studies have shown that the cytosine methylation patterns in MGMT exons are 
altered in nonexpressing tumors cells relative to expressing cells (Pieper, fil...Jll., 
1991; Wang, et al., 1992; Cairns-Smith and Karran, 1992). Analysis of the role of 
methylation and chromatin structure in transcriptional regulation of MGMT 
expression must therefore consider both the body and promoter of the MGMT gene. 
In this dissertation, the graded methylation and correlations between 
methylation and MGMT expression suggest that in both the promoter and body of 
the MGMT gene, methylation may influence the level of MGMT expression. Several 
studies have attempted to analyze methylation in the MGMT promoter in cells with 
different levels of MGMT expression. One study examining the methylation status 
of Hpall sites in the MGMT promoter failed to show a clear association between 
promoter methylation and MGMT gene expression, although the close proximity of 
the fourteen Hpall sites in the promoter region precluded resolution, by Southern 
blot, of the methylation status of these sites (Von Wronski,~., 1992). Analysis 
of the methylation status of a single site 70 bp upstream of the transcription start 
site demonstrated a negative, but not absolute association between methylation and 
MGMT expression, although MGMT promoter activity studies demonstrated that 
deletion of 76 bp 5' from, and including this site did not alter promoter strength 
(Harris, et al., 1992). Another study examining methylation at Hpall sites in the 
MGMT promoter concluded that the promoter was methylated to a greater extent 
in MGMT expressing cell lines compared to nonexpressors, although this study also 
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used Southern blot analysis and thus did not resolve the relevant HpaII fragments 
(Nakatsu, et al., 1993). It is unclear from these studies whether the methylation 
status of the MGMT promoter is associated with MGMT expression. Because of 
the single nucleotide resolution of polyacrylamide gels and the very sensitive nature 
of linker-mediated PCR, the analysis of methylation presented here overcame the 
inadequate resolution noted in previous studies. The graded methylation across the 
cell lines at 21 of 25 CpGs tested in the MGMT promoter indicates that the 
methylation status is uniform within each cell line and that there is a close, inverse 
association between overall promoter methylation and MGMT expression (Costello, 
et al., 1994). The overall promoter methylation, expressed as the average "percent 
unmethylated" of all CpG sites, was similar in region I and II. For region I, the 
level was 93 % in SF767, 73 % in Hs683 and 45 % in CLA. In region II, the 
promoter was 100% unmethylated in SF767, 74 % unmethylated in Hs683, 58% 
unmethylated in CLA. These measurements reflect the average methylation within 
a population of MGMT gene alleles. The region II values were expressed relative 
to SF767 because the intensity of cytosine bands corresponding to the more 3' 
cytosines in the plasmid DNA was somewhat diminished, and thus difficult to 
accurately quantitate. As the three 5' most cytosines of CpGs in the plasmid region 
II were similar in degree of unmethylation to those in the SF767 cell line however, 
and as most sites in SF767 region I were completely unmethylated (given the 8.6 % 
average experimental error), it seems reasonable to assume region II cytosines in 
SF767 DNA are nearly 100 % unmethylated. It should be noted that in cells that 
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do not express the MGMT gene, methylation of the promoter, while less than in 
expressing cells, was still only 50 %, rather than 100 % methylation noted in X-
linked inactive genes (Pfeifer, .§_fil., 1990). These data suggest that while inactive 
genes on the X chromosome may be 100 % methylated, complete methylation may 
not be necessary for processes involved in promoter inactivity. Using linker-
mediated PCR with hydrazine-reacted DNA, methylated cytosines are identified by 
the absence of hydrazine reactivity and hence the disappearance of cytosine bands. 
Point mutations that change a cytosine to any other base could also account for the 
disappearance of cytosine bands and would be erroneously interpreted as 
methylated cytosines. This possibility was completely eliminated in the MGMT 
promoter studies by the demonstration that the nucleotide present on the 
complementary DNA strand, and base paired with the base in question, was always 
guanine (unpublished data). These results suggest that an unmethylated promoter 
is required for efficient MGMT expression and that the level of promoter 
methylation is closely associated with the level of MGMT gene expression. 
In contrast to promoter methylation, the relative contribution of methylation 
in the body of genes to the control of gene expression is less understood. However, 
the conserved methylation status in the body of many genes implies that these sites 
are important, at least in genes in which the body methylation correlates with gene 
expression. While methylation in the MGMT promoter correlates inversely with 
MGMT expression, the uniform methylation over the body of the MGMT gene and 
graded methylation at the intron 1 EcoRI site correlated directly with MGMT 
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expression, suggesting that methylation in the body may also influence MGMT 
expression in a graded fashion. Although the intron 1 EcoR I site analysis is 
consistent with the methylation analysis at Hpall sites in the same region, the 
possibility that the inhibition of EcoRI digestion at the internal EcoRI site in 
MGMT intron 1 is a result of a point mutation or small deletion that destroys the 
EcoRI site cannot be excluded. This possibility is unlikely, however, as the 
probability of this specific mutation occurring independently in all 10 of the 
unrelated glioma cell lines tested is exceptionally low. Two limitations of the Hpall 
site methylation analysis should also be acknowledged. First, CpGs within Hpall 
sites (CCGG) account for only 1/16 of all CpGs in a given region of DNA. The 
possibility that the non-Hpall CpGs are not differentially methylated in MGMT+ 
cells relative to MGMT- cells exists but is highly unlikely, as Hhal sites 
(GCGC)(unpublished data) and the EcoRI site in the intron 1 region were also 
differentially methylated. Second, for technical reasons, the analysis of Hpall 
fragments by Southern blot is limited to DNA fragments greater than 300 bp. If 
< 300 bp clusters of Hpall sites exist within the analyzed regions of the body of the 
MGMT gene, many of these sites, if unmethylated, would not be included in the 
methylation analysis. On the other hand, the presence of large probe-recognized 
fragments in the DNA of the MGMT+ cells indicates that all Hpall sites within 
those fragments are methylated, including any potentially clustered Hpall sites. 
Because the body of the MGMT gene is methylated in MGMT expressing normal 
human brain cells and T lymphocytes, the close association between 
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hypomethylation of the MGMT gene and lack of MGMT expression in glioma cell 
lines suggests that maintenance of appropriate levels of methylation in the body of 
the gene may be important for MGMT expression. The picture that emerges from 
the methylation data is that for efficient MGMT transcription, the MGMT promoter 
should be unmethylated and the body of the gene, heavily methylated. Conversely, 
increased methylation in the promoter and decreased body methylation are 
associated with decreased MGMT expression. The graded nature of this 
relationship suggests that methylation and MGMT gene expression are closely, and 
possibly causally, linked. 
Several recent studies suggest that in general, methylation and gene 
expression are causally linked, possibly in both a direct and inverse fashion. A 
study of mutant mice deficient in cytosine methyltransferase (MTase) provided 
examples in which preventing normal methylation inhibited gene expression in some 
genes and, in other genes, caused activation of normally silent genes (Li, _gt_fil., 
1993). For example, in normal mice, the methylated (in the promoter), paternal 
allele of the H19 gene is transcriptionally inactive (Bartolomei et al., 1991), but in 
MTase deficient mice, this H19 allele is unmethylated and expressed. In contrast, 
2 kb of an intron of the transcriptionally active maternal lgf-2r gene is methylated 
in normal mice (Stoger, et al., 1993), but in MTase deficient mice, this intron region 
is unmethylated and the maternal Igf-2r gene is not expressed (Li, et al., 1993). 
These studies indicate that, at least for the H19 and Igf-2r genes, methylation and 
gene expression are causally linked. These studies also demonstrate that 
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methylation can have completely opposite effects on gene expression, apparently 
depending on the region of the gene involved. Methylation in the promoter of genes 
inhibits gene expression, whereas methylation in introns may facilitate gene 
expression. In other genes, a cause and effect relationship between methylation and 
gene expression has been tested with the methylation inhibitor 5-azacytidine. For 
example, the 5-azacytidine-induced reactivation of the inactive, methylated HPRT 
gene occurs only following significant demethylation of the 5' CpG island (Sasaki, 
et al., 1992). Several studies have attempted to establish a causal relationship 
between MGMT gene methylation and MGMT expression by treating MGMT+ and 
MGMT- tumor cells with 5-azacytidine. Treatment of a MGMT+ tumor cell line 
with 5-azacytidine decreased methylation in the body of the gene to a level 
comparable to a MGMT- cell line and significantly decreased MGMT mRNA levels 
(Pieper, .rt_fil., 1991). Additionally, two reports (Mitani, et al., 1989; Ishida and 
Takashi, 1988) have demonstrated that treatment of MGMT- human cell lines with 
5-azacytidine did not restore MGMT expression. These studies suggest that the 
absence of MGMT expression is not solely due to a reversible promoter 
hypermethylation, as has been demonstrated in the X-linked HPRT gene, but may 
also involve methylation in the body. In contrast, an induction in MGMT 
expression was observed following exposure to 5-azacytidine in two additional 
MGMT nonexpressing cell lines, although these studies did not assess methylation 
in the body of the gene (von Wronski and Brent, 1994). In sum, these experiments 
suggest that 5-azacytidine-induced demethylation can increase or decrease MGMT 
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expression, depending on the pre-treatment methylation status and the extent of 
induced demethylation of the MGMT gene. The interpretation of these results is 
complicated by the fact that 5-azacytidine, in addition to altering gene expression 
through demethylation of DNA, can also lead to chromosomal damage and 
instability that also potentially alter gene expression. Other more specific methods 
of inhibiting methylation, such as inhibition of MTase expression through MTase 
antisense oligonucleotides, might be more appropriate in addressing a potentially 
causal relationship between methylation and MGMT gene expression. Recent in 
vitro studies indicate that methylation of an MGMT promoter-CAT construct with 
bacterial CpG methylases reduced CAT gene expression, although it should be noted 
that both the MGMT promoter and body of the CAT gene were methylated in these 
studies (Harris, et al., 1994). This in vitro study of methylated and unmethylated 
MGMT promoter-CAT constructs and the 5-azacytidine studies are inherently 
incapable of addressing the relative contribution of methylation in the body and 
methylation in the promoter to MGMT gene expression. Although the results of 
most of these MGMT gene methylation studies, aside from their limitations, seem 
to indicate that there is a cause/effect relationship between methylation and MGMT 
gene expression, the events leading to the changes in methylation have not been 
identified. Conclusive testing of the potential cause/effect relationship between 
methylation and MGMT expression relies first on the identification of the 
process(es) leading to aberrant MGMT gene methylation. The expectation is that 
methylation changes will precede, or occur concurrent with, MGMT gene 
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inactivation, if altered methylation actually causes suppression of MGMT 
transcription. 
Although a temporal relationship between changes in methylation and MGMT 
expression has not been investigated in gliomas or glioma cell lines, deficits in 
maintenance of normal methylation during tumorigenesis or tumor progression 
could be one mechanism by which the MGMT promoter (CpG island) 
hypermethylation and body hypomethylation, and possibly loss of expression, of the 
MGMT gene occurs. Clearly, this issue needs to be addressed in human glioma 
samples, as the methylation status of the DNA in the glioma cells used in this 
dissertation may be influenced by cell culture conditions as well as tumorigenesis. 
Examining potential MGMT methylation changes in the well defined stages of 
glioma progression could yield information about the temporal relationship between 
alterations in methylation and MGMT expression and might eventually be useful 
in identifying MGMT deficient, BCNU-sensitive gliomas. 
One potential mechanism mediating the relationship between methylation and 
MGMT expression involves alterations in chromatin structure. Analysis of Avall 
and Mspl accessibility demonstrated that chromatin structure and methylation in 
the MGMT promoter are closely linked. The MGMT promoter was much more 
accessible to RE in cells with a completely unmethylated promoter compared to cells 
with promoters that are, on average, only 74 % unmethylated (Hs683) or 50 % 
unmethylated (CLA). The close association between methylation and chromatin 
structure was demonstrated by the graded fashion in which accessibility of.at least 
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3 Mspl sites correlated with methylation. The accessibility of all sites tested over 
372 nt (712-1084) of the basal promoter in the nuclei from SF767 cells (fig. 27) 
indicates that this may be a nucleosome-free region, as DNA wrapped in 
nucleosomes would be protected from restriction enzyme digestion (Tazi and Bird, 
1990). Conversely, the inaccessibility of the promoter at all sites over 372 nt in the 
CLA cells (fig. 27) suggests that nucleosomes and/or methylated DNA binding 
proteins are present and possibly involved in setting the transcriptionally inactive 
state of the promoter in these cells. The results of the chromatin structure analysis 
of the MGMT promoter are consistent with the idea that chromatin structure is an 
important part of MGMT transcription. Similar to the promoter, methylation and 
accessibility in the body of the gene were also closely associated in the expected 
fashion. The unmethylated gene in nuclei from three MGMT- cell lines was more 
accessible at three Mspl sites, relative to the methylated gene in nuclei from two 
MGMT+ cell lines. The only Mspl accessible sites in MGMT+ nuclei 
corresponded exactly to the few unmethylated sites in this region within MGMT+ 
nuclei. These data demonstrate that methylation and chromatin structure in the 
body of the MGMT gene are intimately associated and suggest that MeCPs may be 
mediating this association. These differences in accessibility can also be detected 
with Alul, which cleaves DNA at non-CpG containing sites. This suggests that 
either the Alul sites are sufficiently close to a CpG and are blocked by a nearby 
MeCP, or that some other component of the chromatin structure, such as histones, 
is present in MGMT+ cells but is absent or displaced from the MGMT gene in 
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Figure 27. Summary diagram of in vivo footprints in, and restriction enzyme 
accessibility to the MGMT promoter in MGMT+ (SF767) and MGMT- (CLA) 
glioma cells. Filled rectangle (I) indicates footprinted Spl site, open rectangle 
indicates unoccupied Spl sites. Filled oval denotes footprinted site of undefined 
nature and the open oval is the same site unoccupied. .a. indicates restriction 
enzyme accessible site; M, Mspl, A, Avail. 
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MGMT- cells. The latter possibility in unlikely though, as DNAsel, which readily 
cleaves histone-free DNA but not DNA within nucleosomes, does not cleave the 
MGMT gene in any of the nuclei. The ~ssociation between decreased Mspl/Alul 
accessibility and active transcription in these cells however, is surprising, as 
transcription is generally associated with a more open, accessible chromatin 
conformation. A mechanism by which the more "closed" chromatin conformation 
in the body of genes might facilitate transcription has not been defined. The 
identical nature of the closed conformation in all MGMT+ cell lines tested, and the 
absence from all three MGMT- cell lines however, suggests that there is some 
functional importance associated with the chromatin structure in the body of the 
MGMT gene. Additionally, the fact that more than 30 unrelated cell lines are 
differentially methylated in the body of the gene (Pieper, .rtJtl., 1991; Wang, .rtJtl., 
1992) in the same manner described here, suggests that disruption of the 
methylation-related chromatin structure may be a common event contributing to 
loss of MGMT expression. The results of the chromatin structure analysis of the 
body and promoter are consistent with the idea that chromatin structure is an 
important part of MGMT transcription. The chromatin structure in the promoter 
of the gene may influence MGMT expression by allowing or excluding transcription 
factor access to relevant promoter sequences. 
The methylation-related chromatin structure in the MGMT promoter is closely 
associated with in vivo transcription factor occupancy. In addition to the general 
association between accessible chromatin and transcription factor occupancy, 
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several footprints that are positioned closely to restriction enzyme accessible sites 
reveal specific examples of this association. For example, the protected guanine at 
nt 852 was only 3 nt away from an accessible Mspl site and the presumably Spl 
protected guanine at 965 was only 7 nt away from an accessible Avail site (fig. 27). 
Spl is the only detectable factor interacting with the minimal promoter elements (nt 
886-955), indicating that Spl may be sufficient, in conjunction with protein-protein 
interactions, for basal level MGMT transcription. DNA-protein interactions were 
not detected on the opposite strand (nontranscribed strand) in the basal promoter 
(Russell Pieper, personal communication), which includes an imperfect Spl 
consensus sequence. The possibility that other transcription factor-promoter 
interactions relevant to basal expression occur at non-guanine residues cannot be 
excluded, although there are no other known transcription factor sites within the 
minimal promoter elements. In fact, no other DNA-protein interactions can be 
detected at guanines on either strand of the entire 1157 bp MGMT promoter 
(Russell Pieper, personal communication). It is not unexpected that there are no 
discernable footprints in the promoter of Hs683 cells, which express very low levels 
of MGMT, because the Hs683 promoter is inaccessible, relative to SF767. It is 
probable that Spl does nevertheless interact with the Hs683 promoter, but only too 
infrequently, as dictated by accessibility, to detect with DMS footprinting. The 
footprint at nt 845-852, while not within the proposed minimal promoter, is 
associated with MGMT transcription, as it is present in the expressing cell lines 
and T cells and absent from all three non-expressing glioma cell lines. This 
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presumably expression-related protein-promoter interaction is of note for three 
reasons. First, previous in vitro studies showed that addition of promoter nt 807-
883, which includes the footprinted site, to the minimal promoter did not increase 
MGMT promoter-driven CAT expression (Harris,fil.Jll., 1991), suggesting that these 
sequences are inconsequential to MGMT promoter activity. As the effect of deletion 
of only these sequences from the full promoter was not tested, it remains possible 
that these sequences are important for promoter activity, but that their contribution 
is influenced by interactions with other promoter regions. Such interactions have 
been noted for synergistically functioning, yet distant Spl sites (Su,~., 1991). 
Second, the DNA-protein interaction is novel as it involves nucleotides that do not 
correspond to any known transcription factor binding site. Although the footprinted 
sequence has minimal homology to an Spl site (7 of 10 nt), and several sequences 
that deviate from the canonical Spl site can bind Spl (Brown, .§.Jtl., 1992), the 
pattern of the protected sequence is distinct from the canonical Spl protection, as 
seen at the other 6 footprints in the MGMT promoter. Third, in contrast to the 
single strand Spl footprints, the novel footprint is present on both DNA strands 
(Russell Pieper, personal communication). The data indicate that the protein 
interacting with promoter nucleotides 845-852 is not Spl and suggest that it may 
be a novel transcription factor, or a known transcription factor interacting with a 
novel binding site. Three additional sequences previously described as potential 
Spl sites based on sequence analysis (12), are not protected in any of the cells 
tested, suggesting that these sites do not function as Spl sites in vivo. Since these 
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sites have only marginal similarity to Spl sites (7of10 nt) it is possible that these 
sequences are incapable of binding Spl. These in vivo results further support the 
idea that methylation-related differences in chromatin structure of the MGMT 
promoter determine whether Spl, and possibly other factors necessary for MGMT 
expression, can interact with the MGMT promoter. 
Given some latitude for speculation, the correlative data presented in this 
dissertation can be incorporated into a model of MGMT transcription. The MGMT 
promoter, like other CpG island-containing promoters, must be maintained in the 
unmethylated state for efficient transcription initiation. Maintenance of the 
unmethylated state could occur through binding of the 6 Spl molecules per 
promoter. If these sites are occupied by Spl shortly after DNA replication, Spl may 
block access to the basal promoter by cytosine MTase, and thus, maintain the 
unmethylated state. This part of the model is compatible with the fact that several 
CpGs 5' to the Spl sites are not protected by proteins, and are also methylated in 
MGMT+ and MGMT- cells (Qian, ..tl__fil., 1994). Spl may therefore serve two 
purposes in MGMT expression. Spl may help maintain the unmethylated state of 
the basal promoter and likely also facilitates the assembly of the transcription 
complex. There is no obvious spatial pattern to the occupied Spl sites, although 
all 6 Spl molecules contact guanines which are likely on the same face of the double 
helix. This arrangement may be relevant to the known transcription activating 
function of Spl. Spl is not bound to the methylated basal promoter possibly 
because MeCPs (or other chromatin structure proteins) bind these sites before or 
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more efficiently than Spl. Alternatively, the methylated promoter, similar to other 
methylated sequences, may be replicated at a later stage when much of the Spl has 
been committed to other gene regulatory sequences. According to these 
suppositions, the affinity of Spl for each site in the unmethylated MGMT promoter 
would be much higher than the affinity of MeCPs (if MeCPs bind unmethylated 
DNA at all). As methylation increases to 25% (as in Hs683) the relative affinities 
may approximate each other and transcription may be initiated much less 
frequently, only when Spl can occupy a critical number of sites. These less frequent 
Spl-promoter interactions would probably not be detectable by standard DMS 
footprinting. Between 25% and 50% basal promoter methylation, the promoter 
affinity shifts in favor of MeCP, resulting in exclusion of Spl and suppression of 
transcription initiation. Analysis of the Sp 1 footprints at all stages of the cell cycle 
in synchronized cells might provide indirect evidence for thi.s scheme. Any model 
of MGMT transcription must also incorporate the relative efficiency of transcription 
elongation, as the methylation-related chromatin structure in the body of the 
MGMT gene is different in MGMT+ compared to minimally MGMT+ cells (or 
MGMT+ cells treated with 5-azacytidine) and might facilitate or impede the 
transcription elongation complex. Since the changes in chromatin structure in the 
body of the gene are clearly related to methylation, MeCPs are possible candidates 
for mediating this relationship. Binding of MeCPs across the body of the gene 
could establish an efficiently transcribed DNA conformation by preventing binding 
of other proteins, such as histone Hl, that are known to contribute to 
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transcriptionally inactive chromatin. Binding of MeCPs in the body of the gene 
would likely be weak because the CpG density is low relative to CpG islands. Thus, 
the MeCPs in the body of the gene could facilitate transcription by preventing the 
binding ofhistone Hl-like proteins, while being easily displaced by RNA polymerase 
II during elongation. Alternatively, MeCPs may be bound to the body of the gene 
at specific sites to properly position the gene sequences within a transcriptionally 
active region of the nucleus. MeCPs might accomplish this through maintaining 
appropriate DNA attachment to the nuclear matrix, or orienting the exons near 
each other on adjacent chromatin loops to facilitate accurate and immediate 
splicing events. The conserved chromatin structure in the MGMT+ cells and 
disrupted chromatin structure at the same, specific sites in each of the minimally 
MGMT+ and MGMT- cells supports the idea that chromatin structure in the body 
of the gene is relevant to transcription. 
The findings that the promoter in the MGMT expressing cells is unmethylated, 
accessible and occupied by transcription factors, suggest that MGMT expression is 
dependent on these factors. Since MGMT expression is a major determinant in 
sensitivity versus resistance to BCNU (Day, et al., 1980), methylation, chromatin 
structure and transcription factor occupancy of the promoter could be viewed as 
critical elements of the molecular mechanisms that determine the chemosensitivity 
of these glioma cells. In support of this, MGMT expressing SF767 cells are much 
more resistant to BCNU compared to the non-expressing CLA cells (Sariban, et al., 
1987; Mitchell, et al., 1992). The fact that gliomas of oligodendrocytic origin are 
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especially sensitive to nitrosourea-based chemotherapy (MacDonald, ~., 1990) 
implies that MGMT gene inactivation may be a frequent event, possibly mediated 
by changes in methylation, chromatin structure and transcription factor access, in 
these tumors. Consistent with this speculation, a recent study has demonstrated 
that oligodendroglioma tumor samples are in fact very low in MGMT activity (Nutt, 
et al., 1994). Furthermore, as inhibition of MGMT in tumor cells is a current goal 
of BCNU-based chemotherapy, the "open" chromatin conformation of the promoter 
in MGMT-expressing (and hence BCNU resistant) glioma cells may be a good 
target for inhibition of MGMT expression, possibly through triple helix formation. 
To be of therapeutic value, inhibition of MGMT through triple helix forming 
oligonucleotides should be tumor specific. Since the MGMT promoter in normal 
and BCNU-resistant tumor cells is likely identical, the tumor specificity of MGMT 
inhibitors relies on tumor-specific delivery of these molecules. Direct delivery of 
BCNU to glioma cells has been accomplished by implanting BCNU-saturated 
anhydrous wafers directly into the tumor area following surgery. The results from 
phase I clinical trials of this therapy in glioma patients indicates that the BCNU-
induced systemic side-effects are significantly reduced or absent (Brem, et al., 1991). 
Incorporation of potential inhibitors of MGMT expression, such as triple helix 
forming oligonucleotides, into the slow-release wafers might then also provide 
tumor-specificity of MGMT inhibition and hence sensitization to BCNU. Obviously, 
testing triple helix-forming oligonucleotides in MGMT inhibition is the next 
preliminary step towards achieving these therapeutic goals. 
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